Blueprint

0001654954-17-000894.txt : 20170209 0001654954-17-000894.hdr.sgml : 20170209 20170209161608 ACCESSION NUMBER: 0001654954-17-000894 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170209 DATE AS OF CHANGE: 20170209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 17587761 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm QUARTERLY REPORT Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2016

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction incorporation		(IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer ☐ Accelerated filer ☒

Non-accelerated filer ☐ Smaller reporting company ☐

(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Class of Stock	No. Shares Outstanding	Date
Common	190,965,450	February 3, 2017

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1.		Page

	Condensed Balance Sheets at December 31, 2016 and September 30, 2016 (unaudited)	3

	Condensed Statements of Operations for the three months Ended December 31, 2016 and 2015 (unaudited)	4

	Condensed Statements of Cash Flows for the three months Ended December 31, 2016 and 2015 (unaudited)	5

	Notes to Condensed Financial Statements (unaudited)	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risks	27

Item 4.	Controls and Procedures	27

PART II

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28

Item 6.	Exhibits	28

	Signatures	29

CEL-SCI CORPORATION

CONDENSED BALANCE SHEETS

(UNAUDITED)

	DECEMBER 31,	SEPTEMBER 30,
ASSETS	2016	2016

CURRENT ASSETS:
Cash and cash equivalents	$2,386,673	$2,917,996
Receivables	4,128	394,515
Prepaid expenses	866,987	981,677
Deposits - current portion	154,995	154,995
Inventory used for R&D and manufacturing	694,504	1,008,642
Deferred rent - current portion	415,003	429,821

Total current assets	4,522,290	5,887,646

RESEARCH AND OFFICE EQUIPMENT, net	229,676	226,216

PATENT COSTS, net	247,267	256,547
DEFERRED RENT - net of current portion	3,257,739	3,406,921

DEPOSITS	1,670,917	1,820,917

TOTAL ASSETS	$9,927,889	$11,598,247

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

CURRENT LIABILITIES:
Accounts payable	$2,741,353	$3,091,512
Accrued expenses	319,476	378,672
Due to employees	476,413	538,278
Derivative instruments, current portion	249,157	-
Other current liabilities	7,203	3,310

Total current liabilities	3,793,602	4,011,772

Derivative instruments - net of current portion	1,533,549	8,394,934
Deferred revenue	125,000	125,000
Other Liabilities	42,447	22,609

Total liabilities	5,494,598	12,554,315

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $.01 par value-200,000 shares authorized;
-0- shares issued and outstanding	-	-
Common stock, $.01 par value - 600,000,000 shares authorized;
190,931,286 and 155,962,079 shares issued and outstanding
at December 31, 2016 and September 30, 2016, respectively	1,909,313	1,559,621
Additional paid-in capital	284,655,153	283,152,288
Accumulated deficit	(282,131,175)	(285,667,977)

Total stockholders' equity (deficit)	4,433,291	(956,068)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$9,927,889	$11,598,247

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED DECEMBER 31, 2016 and 2015

(UNAUDITED)

	2016	2015

GRANT INCOME AND OTHER	$17,258	$20,976

OPERATING EXPENSES:
Research and development	4,024,856	5,169,507
General & administrative	1,407,009	634,601

Total operating expenses	5,431,865	5,804,108

OPERATING LOSS	(5,414,607)	(5,783,132)

GAIN ON DERIVATIVE INSTRUMENTS	8,928,312	8,122,960

INTEREST INCOME, NET	23,097	1,985

NET INCOME AVAILABLE TO COMMON SHAREHOLDERS	$3,536,802	$2,341,813


NET INCOME PER COMMON SHARE
BASIC	$0.02	$0.02
DILUTED	$0.01	$0.02

WEIGHTED AVERAGE COMMON SHARES
OUTSTANDING
BASIC	149,860,777	109,768,502
DILUTED	152,117,711	111,639,785

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

THREE MONTHS ENDED DECEMBER 31, 2016 and 2015

(UNAUDITED)

	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$3,536,802	$2,341,813
Adjustments to reconcile net income to
net cash used in operating activities:
Depreciation and amortization	30,737	41,741
Issuance of common stock and options for services	78,553	329,195
Equity based compensation	312,375	427,910
Common stock contributed to 401(k) plan	38,372	40,995
Loss on retired equipment	1,187	115
Gain on derivative instruments	(8,928,312)	(8,122,960)
(Increase)/decrease in assets:
Receivables	85,046	75,206
Deferred rent	164,000	176,825
Prepaid expenses	96,507	51,628
Inventory used for R&D and manufacturing	314,138	58,798
Deposits	150,000	150,000
Increase/(decrease) in liabilities:
Accounts payable	(75,029)	(1,666,792)
Accrued expenses	(59,196)	280,032
Deferred revenue	-	(1,639)
Due to employees	17,110	(25,056)
Deferred rent liability	(1,496)	4,245

Net cash used in operating activities	(4,239,206)	(5,837,944)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	-	(14,831)

Net cash used in investing activities	-	(14,831)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	3,709,931	10,550,538
Payments on obligations under capital lease	(2,048)	(2,194)

Net cash provided by financing activities	3,707,883	10,548,344

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(531,323)	4,695,569

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	2,917,996	5,726,682

CASH AND CASH EQUIVALENTS, END OF PERIOD	$2,386,673	$10,422,251

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

THREE MONTHS ENDED DECEMBER 31, 2016 and 2015

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

	2016	2015
Decrease in receivable due under the litigation funding arrangement offset
by the same amount payable to the legal firm providing the services	$305,341	$366,267
Research and office equipment included in accounts payable	-	6,814
Capital lease payments included in accounts payable	372	739
Property and equipment acquired through capital lease	26,104	-
Fair value of warrants issued in connection with public offering	2,316,084	5,060,771
Financing costs included in accounts payable	77,987	21,000
Prepaid consulting services paid with issuance of common stock	(18,183)	8,177



Cash paid for interest expense	$12	$33,260

See notes to condensed financial statements.

CEL-SCI CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED DECEMBER 31, 2016 AND 2015 (UNAUDITED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2016.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2016 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2016 is derived from the September 30, 2016 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2016 and 2015 are not necessarily indicative of the results to be expected for the entire year.

The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2016 and September 30, 2016.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred Rent (Asset) –Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

New Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.

OPERATIONS AND FINANCING

The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from loans and the public and private sale of its common stock. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. Currently, the partial clinical hold has had a significant impact on the Company’s market capital, and as such, may impact the Company’s ability to attract new capital. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

The Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. During the three months ended December 31, 2016, the Company raised approximately $3.7 million net proceeds from a public offering. To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it will either have to slow or delay the Phase 3 clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding. The Phase 3 study is currently on partial clinical hold by the FDA. The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $36.0 million as of December 31, 2016 on direct costs for the Phase 3 clinical trial. The total remaining cash cost of the clinical trial is estimated to be approximately $13.5 million. It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g. the manufacturing of the drug. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen. The Company has filed an amendment to the original Phase 3 protocol for it head and neck cancer study with the FDA to allow for this expansion in patient enrollment. Should the FDA allow the amended protocol filed with them to proceed, the remaining cost of the Phase 3 clinical trial will be higher. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.

As of December 31, 2016, the Phase 3 clinical trial for Multikine was on a partial clinical hold.

If the partial clinical hold is not lifted, the Phase 3 study will not be able to be completed to its prespecified endpoints in a timely manner, if at all, and, if the Phase 3 study cannot be completed to its prespecified endpoints, the study would not be able to be used as the pivotal study supporting a marketing application in the United States, and at least one entirely new Phase 3 pivotal study would need to be conducted to provide the pivotal study supporting a marketing application in the United States. Even if the partial clinical hold is lifted, if it is not lifted in a timely fashion, the nature and duration of the partial clinical hold could irreparably harm the data from the Phase 3 study such that it may no longer be able to be used as the pivotal study supporting a marketing application in the United States. Even if the partial clinical hold is lifted in a timely fashion, it remains possible that the regulatory authorities could determine that the Phase 3 study is not sufficient to be used as a single pivotal study supporting a marketing application in the United States.

STOCKHOLDERS’ EQUITY

Stock options, stock bonuses and compensation granted by the Company as of December 31, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans	Shares Reserved for Outstanding Options	Shares Issued	Remaining Options/Shares Under Plans

Incentive Stock Options Plans	3,460,000	1,648,966	N/A	1,511,334
Non-Qualified Stock Option Plans	9,680,000	6,563,284	N/A	2,389,098
Stock Bonus Plans	5,594,000	N/A	4,003,926	1,589,247
Stock Compensation Plan	3,350,000	N/A	2,087,257	1,229,692
Incentive Stock Bonus Plan	16,000,000	N/A	15,600,000	400,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans	Shares Reserved for Outstanding Options	Shares Issued	Remaining Options/Shares Under Plans

Incentive Stock Option Plans	3,460,000	1,648,966	N/A	1,511,334
Non-Qualified Stock Option Plans	9,680,000	6,940,321	N/A	2,059,261
Bonus Plans	5,594,000	N/A	3,161,211	2,431,962
Stock Compensation Plan	3,350,000	N/A	1,985,037	1,331,912
Incentive Stock Bonus Plan	16,000,000	N/A	15,600,000	400,000

Stock option activity:

	Three Months Ended December 31,
	2016	2015
Granted	-	-
Expired	377,037	-
Forfeited	-	22,966

Stock-Based Compensation Expense

	Three months Ended December 31,
	2016	2015
Employees	$312,375	$427,910
Non-employees	$78,553	$329,195

Employee compensation expense includes the expense related to options issued or vested and restricted stock. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts.

Warrants and Non-employee Options

The following chart presents the outstanding warrants and non-employee options, listed by expiration date at December 31, 2016:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant	Exercise Price	Expiration Date	Reference

Series P	2/10/12	590,001	$4.50	3/6/17
Series DD	12/8/16	34,024,000	$0.18	6/8/17	1
Series EE	12/8/16	34,024,000	$0.18	9/8/17	1
Series N	8/18/08	2,844,627	$0.53	8/18/17
Series U	4/17/14	445,514	$1.75	10/17/17	1
Series S	10/11/13 -10/24/14	25,928,010	$1.25	10/11/18	1
Series V	5/28/15	20,253,164	$0.79	5/28/20	1
Series W	10/28/15	17,223,248	$0.67	10/28/20	1
Series X	1/13/16	3,000,000	$0.37	1/13/21
Series Y	2/15/16	650,000	$0.48	2/15/21
Series Z	5/23/16	6,600,000	$0.55	11/23/21	1
Series ZZ	5/23/16	500,000	$0.55	5/18/21	1
Series BB	8/26/16	400,000	$0.55	8/22/21	1
Series FF	12/8/16	1,701,200	$0.16	12/1/21	1
Series CC	12/8/16	17,012,000	$0.20	12/8/21	1
Series AA	8/26/16	5,000,000	$0.55	2/22/22	1
Consultants	3/6/12- 7/1/16	575,000	$0.37- $3.50	3/5/17- 6/30/19	2

Derivative Liabilities

The table below presents the warrant liabilities and their respective balances at the balance sheet dates:

	December 31, 2016	September 30, 2016
Series S warrants	$490,040	$3,111,361
Series U warrants	-	-
Series V warrants	202,532	1,620,253
Series W warrants	132,254	1,799,858
Series Z warrants	101,817	970,604
Series ZZ warrants	6,725	70,609
Series AA warrants	84,092	763,661
Series BB warrants	5,916	58,588
Series CC warrants	455,931	-
Series DD warrants	72,353	-
Series EE warrants	176,804	-
Series FF warrants	54,242	-

Total warrant liabilities	$1,782,706	$8,394,934

The table below presents the gains on the warrant liabilities for the three months ended December 31:

	2016	2015
Series S warrants	$2,621,321	$2,826,153
Series U warrants	-	31,186
Series V warrants	1,417,721	3,240,506
Series W warrants	1,667,604	2,025,115
Series Z warrants	868,787	-
Series ZZ warrants	63,884	-
Series AA warrants	679,569	-
Series BB warrants	52,672	-
Series CC warrants	604,492	-
Series DD warrants	370,919	-
Series EE warrants	514,603	-
Series FF warrants	66,740	-

Net gain on warrant liabilities	$8,928,312	$8,122,960

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Issuance of additional Warrants

On December 8, 2016, the Company sold 34,024,000 shares of common stock and warrants to purchase common stock at a price of $0.125 in a public offering. The warrants consist of 17,012,000 Series CC warrants to purchase 17,012,000 shares of common stock, 34,024,000 Series DD warrants to purchase 34,024,000 shares of common stock and 34,024,000 Series EE warrants to purchase 34,024,000 shares of common stock. The Series CC warrants are immediately exercisable, expire in five-years from the offering date and have an exercise price of $0.20 per share. The Series DD warrants are immediately exercisable, expire in six-months from the offering date and have an exercise price of $0.18 per share. The Series EE warrants are immediately exercisable, expire in nine-months from the offering date and have an exercise price of $0.18 per share. In addition, the Company issued 1,701,200 Series FF warrants to purchase 1,701,200 shares of common stock to the placement agent. The FF warrants are exercisable at any time on or after June 8, 2017 and expire on December 1, 2021 and have an exercise price $0.15625. The net proceeds from this offering was approximately $3.7 million. The fair value of the Series CC, DD, EE and FF warrants of approximately $2.3 million on the date of issuance was recorded as a warrant liability.

Expiration of Warrants

On December 6, 2016, 2,625,000 Series R warrants, with an exercise price of $4.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.

On December 22, 2015, 1,200,000 Series Q warrants, with an exercise price of $5.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.

Options and shares issued to Consultants

The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the three months ended December 31, 2016, the Company issued 372,492 shares of common stock, of which 270,000 were restricted shares. The common stock was issued with stock prices ranging between $0.09 and $0.29 per share. During the three months ended December 31, 2015, the Company issued 442,492 shares of common stock, of which 340,000 were restricted shares. The common stock was issued with stock prices ranging between $0.41 and $0.72 per share. Additionally, during the three months ended December 31, 2015, the Company issued a consultant 150,000 options to purchase common stock at $0.60 per share and a fair value of $0.30 per share. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service.

During the three months ended December 31, 2016 and 2015, the Company recorded total expense of approximately $79,000 and $329,000, respectively, relating to these consulting agreements. At December 31, 2016 and September 30, 2016, approximately $30,000 and $48,000, respectively, are included in prepaid expenses. As of December 31, 2016, the Company had 575,000 options outstanding, which were issued to consultants as payment for services. Of these 575,000 outstanding options, 475,000 were vested, all of which were issued from the Non-Qualified Stock Option plans.

FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

●

Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

●

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

●

Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total

Derivative instruments	$490,040	$-	$1,292,666	$1,782,706

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total

Derivative instruments	$3,111,361	$-	$5,283,573	$8,394,934

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2016 and the year ended September 30, 2016:

	(3 months ended)	(12 months ended)
	December 31, 2016	September 30, 2016

Beginning balance	$5,283,573	$6,323,032
Issuances	2,316,084	8,722,073
Realized and unrealized gains	(6,306,991)	(9,761,532)
Ending balance	$1,292,666	$5,283,573

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates, are observable in active markets.

RELATED PARTY TRANSACTIONS

Effective August 31, 2016, Maximilian de Clara, the Company’s then President and a director, resigned for health reasons. In payment for past services, the Company agreed to issue Mr. de Clara 650,000 shares of restricted stock; 325,000 shares upon his resignation and 325,000 on August 31, 2017. At December 31, 2016 and September 30, 2016, the fair value accrued for unissued shares was approximately $22,000 and $101,000, respectively.

On January 13, 2016, the de Clara Trust demanded payment on a note payable, of which the balance, including accrued and unpaid interest, was approximately $1.1 million. The de Clara Trust was established by Maximilian de Clara, the Company’s former President and a director. The Company’s Chief Executive Officer, Geert Kersten, is the trustee and a beneficiary. When the de Clara Trust demanded payment on the note, the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X warrants to the de Clara Trust for approximately $1.1 million. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021.

During the three months ended December 31, 2016 and 2015, the Company paid approximately $0 and $33,000, respectively, in interest expense to Mr. de Clara.

COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

In March 2013, the Company entered into an agreement with Aptiv Solutions, Inc. (which was subsequently acquired by ICON Inc.) to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse ICON for costs incurred. The agreement required the Company to make $600,000 in advance payments which are being credited against future invoices in $150,000 annual increments through December 2017. As of December 31, 2016, the total balance advanced is $150,000, which is classified as a current asset.

In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $20.4 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $6.6 million. During the three months ended December 31, 2016 and 2015, the Company recorded, net of Ergomed’s discount, approximately $1.3 million and $2.0 million, respectively, as research and development expense related to Ergomed’s services.

In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed. One agreement supports the Phase 1 study being conducted at the University of California, San Francisco, or UCSF, for the development of Multikine as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women. The Phase 1 study originally started after the Company signed a cooperative research and development agreement with the U.S. Naval Medical Center, San Diego. In August 2016, the U.S. Navy discontinued this Phase 1 study because of difficulties in enrolling patients. The other agreement focuses on the development of Multikine as a potential treatment for cervical dysplasia in HIV/HPV co-infected women. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.

The Company is currently involved in a pending arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet AG). The Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former third-party CRO, and are seeking payment for damages related to inVentiv’s prior involvement in the Phase 3 clinical trial of Multikine. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in its amended statement of claim.

In an amended statement of claim, the Company asserted the claims set forth above as well as an additional claim for professional malpractice. The arbitrator subsequently granted inVentiv’s motion to dismiss the professional malpractice claim based on the “economic loss doctrine” which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim alongside a claim for breach of contract. The arbitrator denied the remainder of inVentiv’s motion, which had sought to dismiss certain other aspects of the amended statement of claim. In particular, the arbitrator rejected inVentiv’s argument that several aspects of the amended statement of claim were beyond the arbitrator’s jurisdiction.

In connection with the pending arbitration proceedings, inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the alleged use of inVentiv’s name in connection with publications and promotions in violation of the parties’ contract; (iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv’s counterclaims are meritless and intends to vigorously defend against them. However, if such defense is unsuccessful, and inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material adverse effect on the Company’s business, results, financial condition and liquidity.

In October 2015 the Company signed an arbitration funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation expenses. Pursuant to the agreement, an affiliate of Lake Whillans provides the Company with up to $5 million in funding for litigation expenses to support its arbitration claims against inVentiv. The funding is available to the Company to fund the expenses of the ongoing arbitration and will only be repaid if the Company receives proceeds from the arbitration. During the three months ended December 31, 2015, the Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap its fees and expenses for the arbitration at $5 million.

The arbitration hearing on the merits began on September 26, 2016.

Lease Agreements

The Company leases a building near Baltimore, Maryland. The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.

The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets at December 31, 2016 and September 30, 2016.

The Company subleases a portion of its rental space on a month-to-month term lease, which requires a 30 day notice for termination. The Company receives approximately $6,000 per month in rent for the sub-leased space.

The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. In September 2016, the lease was extended through February 28, 2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of approximately $11,000 per month. As of December 31, 2016 and September 30, 2016, the Company has recorded a deferred rent liability of approximately $1,000 and $2,000, respectively.

The Company leases its office headquarters under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per month. As of December 31, 2016 and September 30, 2016, the Company has recorded a deferred rent liability of approximately $18,000.

During the three months ended December 31, 2016, the Company leased office equipment under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment is $505. The lease bears interest at approximately 6.25% per annum. The Company’s previous equipment lease expired on September 30, 2016.

PATENTS

During the three months ended December 31, 2016 and 2015, no patent impairment charges were recorded. For the three months ended December 31, 2016 and 2015, amortization of patent costs totaled approximately $9,000. The total estimated future amortization expense is as follows:

Nine months ending September 30, 2017	$27,433
Year ending September 30,
2018	36,379
2019	34,676
2020	31,483
2021	28,183
2022	24,380
Thereafter	64,733
Total	$247,267

EARNINGS PER COMMON SHARE

The following table provides the details of the basic and diluted earnings per-share computations:

	Three Months Ended December 31, 2016
	Net Income	Weighted Average Shares	EPS

Basic earnings per share	$3,536,802	149,860,777	$0.02
Gain on derivatives (1)	(1,556,754)	2,256,934

Dilutive earnings per share	$1,980,048	152,117,711	$0.01

(1) Includes certain Series CC, DD, EE and FF warrants.

	Three Months Ended December 31, 2015
	Net Income	Weighted Average Shares	EPS

Basic earnings per share	$2,341,813	109,768,502	$0.02
Conversion of note payable	24,841	1,871,283

Dilutive earnings per share	$2,366,654	111,639,785	$0.02

The gain on derivatives priced lower than the average market price during the period is excluded from the numerator and the related shares are excluded from the denominator in calculating diluted loss per share.

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:

	2016	2015

Options and Warrants	173,654,474	74,776,529
Unvested Restricted Stock	15,100,000	15,100,000
Total	188,754,474	89,876,529

SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company’s lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is cleared for a Phase 3 clinical trial in advanced primary head and neck cancer. Multikine has been cleared by the regulators in twenty four countries around the world, including the U.S. FDA.

On September 26, 2016, the Company received verbal notice from FDA that the Phase 3 clinical trial in advanced primary head and neck cancer has been placed on clinical hold. At such time, enrollment in the Phase 3 study was 926 patients. Pursuant to this communication from FDA, patients currently receiving study treatments can continue to receive treatment, and patients already enrolled in the study will continue to be followed.

On October 21, 2016, the Company received a partial clinical hold letter from FDA and, on November 18, 2016, the Company submitted a response to FDA’s partial clinical hold letter.

In its partial clinical hold letter, FDA identified the following specific deficiencies: a) FDA stated that there is an unreasonable and significant risk of illness or injury to human subjects and cited among other things the absence of prompt reports by the Company to the FDA of IDMC recommendations to close the study entirely (made in spring of 2014) or at least to close it to accrual of new patients (made in spring of 2016); b) FDA stated that the investigator brochure is misleading, erroneous, and materially incomplete; and c) FDA stated that the plan or protocol is deficient in design to meet its stated objectives. In its partial clinical hold letter, FDA also identified the information needed to resolve these deficiencies. In addition, FDA’s partial clinical hold letter included two requests relating to quality information regarding the Company’s investigational final drug product, which were noted by FDA as non-hold issues. The Company believes that its response submitted to FDA on November 18, 2016, addressed each of the deficiencies identified by FDA including detailing its belief that, under the applicable FDA guidance, there was no obligation to report the cited IDMC recommendations to the FDA at the time they were issued, and it also requested a face-to-face meeting with FDA, and outlined the Company’s commitment to diligently work with FDA in an effort to have the partial clinical hold for the study lifted.

On December 8, 2016, FDA advised us that the Agency was denying the Company’s request for a meeting at that time because FDA’s review of the Company’s November 18, 2016 response was ongoing. The Company also was advised that the Company would be receiving a letter addressing its November 18, 2016 response by December 18, 2016.

On December 16, 2016, FDA issued an Incomplete Response To Hold letter to the Company indicating that based on the Agency’s preliminary review of the Company’s November 18, 2016 submission, FDA has determined that it is not a complete response to all of the issues listed in FDA’s clinical hold letter. FDA identified the following specific deficiencies: a) FDA stated that the Company did not provide the information identified as necessary to address FDA’s statement that patients enrolled in the study are exposed to unreasonable and significant risk of illness or injury to human subjects; b) FDA stated that the Company did not provide the information identified as necessary to address FDA’s statement that continued enrollment of patients in the study exposes the patients to unreasonable risks and FDA furthermore stated that the study is unlikely to demonstrate that the addition of the Company’s investigational drug Multikine to the standard of care is superior to standard of care and thus should be terminated for futility; (c) FDA stated that the Company did not provide the information identified as necessary to address FDA’s statement that the investigator brochure is misleading, erroneous, and materially incomplete; (d) FDA stated that the Company did not provide the information identified as necessary to address FDA’s statement that the proposed revised clinical protocol is inadequate in design to meet its stated objectives and FDA furthermore stated that this deficiency cannot be addressed by further revisions to the protocol. In its incomplete response to hold letter, FDA also identified the steps the Company must take to address these deficiencies. In addition, FDA’s incomplete response to hold letter noted with respect to FDA’s two requests relating to quality information regarding the Company’s investigational final drug product, which the Company had been instructed by FDA to submit separately from the response to the partial clinical hold, which again were noted by FDA as non-hold issues, that the Company’s November 18, 2016, submission had not included the information addressing these two requests.

The Company is reviewing all of its options in response to FDA’s incomplete response to hold letter. As an initial matter, the Company plans to send FDA a request accompanied by the required complete meeting package for an in person meeting with the Agency to discuss all matters relating to the partial clinical hold, because, among other things, the Company believes that there may be some misunderstanding regarding its conduct of the Phase 3 clinical trial as well as some misinterpretation of some of the information contained in the response the Company submitted on November 18, 2016 to the partial clinical hold letter. Pending the scheduling of that FDA meeting and resolution of the partial clinical hold issues, the Company expects to prepare a comprehensive submission to FDA detailing its belief, accompanied by what the Company believes to be appropriate supporting data, records, and information reflecting that the Company has taken the steps necessary to address the specific deficiencies identified by FDA, including: a) demonstrating that patients enrolled in the study are not exposed to unreasonable and significant risk of illness or injury; b) demonstrating that continued enrollment of patients in the study does not expose the patients to unreasonable risks and that the study should not be terminated for futility; (c) demonstrating that a supplemented investigator brochure is not misleading, erroneous, or materially incomplete; (d) demonstrating that the proposed revised clinical protocol is adequate in design to meet its stated objectives and that this deficiency can be addressed by the proposed revisions to the protocol.

Subject to the partial clinical hold, the Company’s estimate that the total remaining cash cost of the Phase 3 clinical trial, excluding any costs that will be paid by our partners, would be approximately $13.5 million. Should FDA lift the partial clinical hold and allow the amended protocol submitted to them to proceed, which requires an enrollment of up to 1,273 subjects, the remaining cost of the Phase 3 clinical trial will be higher than currently estimated. This is in addition to the approximately $36.0 million that the Company already had spent on the trial as of December 31, 2016. This number may be affected by the rate of any future patient enrollment, rate of death accumulation in the study, foreign currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated. If FDA will only lift the partial clinical hold with termination of the current study and initiation of a new clinical trial, any such new trial can only be initiated if permitted by FDA and as appropriate other regulatory authorities around the world after the requisite submissions are made to them, and the additional duration and costs of the Phase 3 clinical program would likely exceed those already incurred in connection with the Phase 3 clinical trial. If there is a need to conduct an additional Phase 3 pivotal study, any such requirement would have significant and severe material consequences for us and could impact our ability to continue as a going concern.

The Company will not be able to enroll any additional patients in the Phase 3 study unless FDA lifts the partial clinical hold. In addition, in the spring of 2016, the IDMC recommended to us that new patient enrollment should stop in the Phase 3 study, but patients already on study should continue to be treated and followed. Although the Company had expected to work through the concerns raised by the IDMC while the Company worked through the partial clinical hold with FDA, the IDMC informed us on December 13, 2016, that because the study is on partial clinical hold imposed by FDA, the IDMC has no formal recommendation regarding continuation of the trial at this time. If the partial clinical hold is not lifted by FDA or if it is determined by FDA that the study has been compromised, the study may be terminated, or if the partial clinical hold is lifted by FDA but the IDMC continues to recommend that enrollment not be allowed to continue, the study may be terminated by the Company.

Multikine is also being used in a Phase I study at UCSF in HIV/HPV co-infected men and women with peri-anal warts.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).

All of the Company’s projects are under development. As a result, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company’s expenses will continue to exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, and the construction of the Company’s laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. Additionally, the partial clinical hold may also impact the Company’s ability to attract new capital. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company is taking cost-cutting initiatives, as well as exploring other sources of funding to finance operations over the next 12 months. However there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

The Company estimates the total remaining cash cost of the Phase 3 trial, with the exception of the parts that will be paid by its licensees, Teva Pharmaceuticals and Orient Europharma, to be approximately $13.5 million. This is in addition to approximately $36 million which has been paid as of December 31, 2016. It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g. the manufacturing of the drug. This number can be affected by the speed of enrollment, rate of death of patients, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 trial will be higher than currently estimated.

In April 2013, the Company announced that it had replaced the CRO running its Phase 3 clinical trial. This was necessary since the patient enrollment in the study dropped off substantially following a takeover of the CRO which caused most of the members of the CRO’s study team to leave the CRO. The Company announced that it had hired two CRO’s who will manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials. Both CRO’s helped the Company expand the trial to over 80 clinical sites globally. As of December 31, 2016, the study has enrolled 926 patients.

Under a co-development agreement, Ergomed will contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount, only from sales for head and neck cancer. Ergomed, a privately-held firm headquartered in Europe with global operations, has entered into numerous similar co-development agreements, including one with Genzyme (purchased by Sanofi in 2011 for over $20 billion). Ergomed will be responsible for the new patient enrollment.

During the three months ended December 31, 2016, the Company’s cash decreased by approximately $531,000. Significant components of this decrease include net proceeds from the sale of the Company’s stock of approximately $3.7 million offset by net cash used to fund the Company’s regular operations, including its Phase 3 clinical trial, of approximately $4.2 million and payments on capital leases of approximately $2,000. During the three months ended December 31, 2015, the Company’s cash increased by approximately $4.7 million. Significant components of this increase include net proceeds from the sale of the Company’s stock of approximately $10.6 million offset by net cash used to fund the Company’s regular operations, including its Phase 3 clinical trial, of approximately $5.8 million, purchases of equipment of approximately $15,000 and payments on capital leases of approximately $2,000.

On December 8, 2016, the Company sold 34,024,000 shares of common stock and warrants to purchase common stock at a price of $0.125 in a public offering. The warrants consist of 17,012,000 Series CC warrants to purchase 17,012,000 shares of common stock, 34,024,000 Series DD warrants to purchase 34,024,000 shares of common stock and 34,024,000 Series EE warrants to purchase 34,024,000 shares of common stock. The Series CC warrants are immediately exercisable, expire in five-years and have an exercise price of $0.20 per share. The Series DD warrants are immediately exercisable, expire in six-months and have an exercise price of $0.18 per share. The Series EE warrants are immediately exercisable, expire in nine-months and have an exercise price of $0.18 per share. In addition, the Company issued 1,701,000 Series FF warrants to purchase 1,701,000 shares of common stock to the placement agent. The FF warrants are exercisable at any time on or after June 8, 2017 and expire on December 1, 2021 and have an exercise price $0.15625. The net proceeds to CEL-SCI from this offering was approximately $3.7 million, excluding any future proceeds that may be received from the exercise of the warrants.

Inventory decreased by approximately $314,000 at December 31, 2016 as compared to September 30, 2016, due to the timing of supplies purchased and used in the manufacturing of Multikine for the Phase 3 clinical trial. In addition, receivables decreased by approximately $390,000, primarily due to the timing of payments reimbursed under the litigation funding arrangement noted above.

Results of Operations and Financial Condition

During the three months ended December 31, 2016, research and development expenses decreased by approximately $1.1 million compared to the three months ended December 31, 2015. The Company is continuing the Phase 3 clinical trial subject to the partial clinical hold, and research and development fluctuates based on the activity level of the clinical trial.

During the three months ended December 31, 2016, general and administrative expenses increased by approximately $772,000 compared to the three months ended December 31, 2015. This increase is primarily due to an approximate $1.1 million gain on de-recognition of legal fees to record the transfer of the liability from the Company to Lake Whillans that existed prior to the execution of the financing agreement. The gain on de-recognition of legal fees is recorded as a reduction of general and administrative expenses in the three months ended December 31, 2015, offset by an approximate $366,000 decrease in employee and non-employee stock compensation due to the decrease in the market value of the common stock and 70,000 fewer shares issued in the three months ended December 31, 2016.

The gain on derivative instruments of approximately $8.9 million for the three months ended December 31, 2016 was the result of the change in fair value of the derivative liabilities during the quarter. This change was caused by decreases in the share price of the Company’s common stock.

Net interest income was approximately $23,000 for the three months ended December 31, 2016, which consisted of interest income earned on the Company’s cash balances. Net interest income was approximately $2,000 for the three months ended December 31, 2015, which consisted of $25,000 of interest expense on the loan from the Company’s president, offset by interest income of approximately $27,000 earned on the Company’s cash balances.

Research and Development Expenses

The Company’s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

	Three months ended December 31,
	2016	2015

MULTIKINE	$3,939,605	$5,074,425
LEAPS	85,251	95,082

TOTAL	$4,024,856	$5,169,507

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2016. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company does not believe that it has any significant exposures to market risk.

Item 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2016. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of December 31, 2016.

Changes in Internal Control over Financial Reporting

The Company’s management, with the participation of the Chief Executive and Chief Financial Officer, has evaluated whether any change in the Company’s internal control over financial reporting occurred during the first three months of fiscal year 2016. There was no change in the Company’s internal control over financial reporting during the three months ended December 31, 2016.

PART II

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

During the three months ended December 31, 2016 the Company issued 270,000 restricted shares of common stock to consultants for investor relations services.

The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding our business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificate representing these shares bears a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

Item 6. (a) Exhibits

Number

Exhibit

Rule 13a-14(a) Certifications

Section 1350 Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: February 9, 2017	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

EX-31 2 cvm_ex31.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint

EXHIBIT 31

CERTIFICATIONS

I, Geert Kersten, certify that:

I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.


February 9, 2017	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

CERTIFICATIONS

I, Geert Kersten, certify that:

I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.


February 9, 2017	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 3 cvm_ex32.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Blueprint

EXHIBIT 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ending December 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Principal Executive and Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.


February 9, 2017	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive and Principal Financial Officer

EX-101.INS 4 cvm-20161231.xml XBRL INSTANCE DOCUMENT 0000725363 2015-10-01 2015-12-31 0000725363 2016-12-31 0000725363 2016-10-01 2016-12-31 0000725363 2016-09-30 0000725363 CVM:SeriesWMember 2016-12-31 0000725363 CVM:SeriesVMember 2016-12-31 0000725363 CVM:SeriesPMember 2016-12-31 0000725363 CVM:ConsultantsMember 2016-12-31 0000725363 CVM:Level1Member 2016-12-31 0000725363 CVM:Level1Member 2016-09-30 0000725363 CVM:Level2Member 2016-12-31 0000725363 CVM:Level2Member 2016-09-30 0000725363 CVM:Level3Member 2016-12-31 0000725363 CVM:Level3Member 2016-09-30 0000725363 CVM:TotalMember 2016-12-31 0000725363 CVM:TotalMember 2016-09-30 0000725363 CVM:IncentiveStockOptionPlansMember 2016-12-31 0000725363 CVM:NonQualifiedStockOptionPlansMember 2016-12-31 0000725363 CVM:StockBonusPlansMember 2016-12-31 0000725363 us-gaap:StockCompensationPlanMember 2016-12-31 0000725363 CVM:SeriesNMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesPMember 2016-10-01 2016-12-31 0000725363 CVM:ConsultantsMember 2016-10-01 2016-12-31 0000725363 2015-09-30 0000725363 CVM:SeriesSMember 2016-12-31 0000725363 CVM:SeriesSMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesUMember 2016-12-31 0000725363 CVM:SeriesUMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesVMember 2016-10-01 2016-12-31 0000725363 CVM:IncentiveStockBonusPlansMember 2016-12-31 0000725363 2015-10-01 2016-09-30 0000725363 2015-12-31 0000725363 CVM:IncentiveStockOptionPlansMember 2016-09-30 0000725363 CVM:NonQualifiedStockOptionPlansMember 2016-09-30 0000725363 CVM:StockBonusPlansMember 2016-09-30 0000725363 us-gaap:StockCompensationPlanMember 2016-09-30 0000725363 CVM:IncentiveStockBonusPlansMember 2016-09-30 0000725363 CVM:SeriesXMember 2016-12-31 0000725363 CVM:SeriesWMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesYMember 2016-12-31 0000725363 CVM:SeriesYMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesNMember 2016-12-31 0000725363 CVM:SeriesXMember 2016-10-01 2016-12-31 0000725363 2017-02-03 0000725363 CVM:SeriesDdMember 2016-12-31 0000725363 CVM:SeriesEeMember 2016-12-31 0000725363 CVM:SeriesZMember 2016-12-31 0000725363 CVM:SeriesZzMember 2016-12-31 0000725363 CVM:SeriesBbMember 2016-12-31 0000725363 CVM:SeriesFfMember 2016-12-31 0000725363 CVM:SeriesCcMember 2016-12-31 0000725363 CVM:SeriesAaMember 2016-12-31 0000725363 CVM:SeriesDdMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesEeMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesZMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesZzMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesBbMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesFfMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesCcMember 2016-10-01 2016-12-31 0000725363 CVM:SeriesAaMember 2016-10-01 2016-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CEL SCI CORP 0000725363 10-Q 2016-12-31 false --09-30 No No Yes Accelerated Filer Q1 2017

0.01

200000

0.01

600000000

190965450

9927889

11598247

1670917

1820917

3257739 3406921

247267

256547

229676

226216

4522290

5887646

415003

429821

694504

1008642

154995

866987

981677

4128

394515

2386673

2917996

5726682

10422251

7203

3310

249157

476413

538278

319476

378672

2741353

3091512

3793602

4011772

42447

22609

125000

1533549

8394934

5494598

12554315

-282131175

-285667977

284655153

283152288

1909313

1559621

4433291

-956068

9927889

11598247

190931286

155962079

190931286

155962079

5169507

4024856

634601

1407009

5804108

5431865

8122960

8928312

-5783132

-5414607

1985

23097

2341813

3536802

0.02

0.01

0.02

111639785

152117711

109768502

149860777

329195

78553

41741

30737

-40995

-38372

427910

312375

-115

-1187

150000

-58798

-314138

-51628

-96507

176825 164000

-75206

-85046

-5837944

-4239206

4245

-1496

-25056

17110

-1639

280032

-59196

-1666792

-75029

14831

-14831

10550538

3709931

10548344

3707883

2194

2048

4695569

-531323

33260

366267

305341

8177 -18183 21000 77987 739 372

Basis of Presentation   The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2016.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2016 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2016 is derived from the September 30, 2016 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2016 and 2015 are not necessarily indicative of the results to be expected for the entire year.   The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.   Summary of Significant Accounting Policies:   Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.   Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.   Research and Development Costs - Research and development costs are expensed as incurred.   Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of December 31, 2016 and September 30, 2016.   Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.   Deferred Rent (Asset) –Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.   Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.   The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.   The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.   Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.   New Accounting Pronouncements   In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.

The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials.  The Company has funded such costs with proceeds from loans and the public and private sale of its common stock.  The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts.  Currently, the partial clinical hold has had a significant impact on the Company’s market capital, and as such, may impact the Company’s ability to attract new capital. To date, the Company has not generated any revenue from product sales.  The ability of the Company to complete the necessary clinical trials and obtain US Food & Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.   The Company is currently running a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. During the three months ended December 31, 2016, the Company raised approximately $3.7 million net proceeds from a public offering. To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.  If the Company does not raise the necessary amounts of money, it will either have to slow or delay the Phase 3 clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding. The Phase 3 study is currently on partial clinical hold by the FDA. The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   Since the Company launched its Phase 3 clinical trial for Multikine, the Company has spent approximately $36.0 million as of December 31, 2016 on direct costs for the Phase 3 clinical trial.  The total remaining cash cost of the clinical trial is estimated to be approximately $13.5 million.  It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g. the manufacturing of the drug.  This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen.  The Company has filed an amendment to the original Phase 3 protocol for it head and neck cancer study with the FDA to allow for this expansion in patient enrollment. Should the FDA allow the amended protocol filed with them to proceed, the remaining cost of the Phase 3 clinical trial will be higher. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.   As of December 31, 2016, the Phase 3 clinical trial for Multikine was on a partial clinical hold.    If the partial clinical hold is not lifted, the Phase 3 study will not be able to be completed to its prespecified endpoints in a timely manner, if at all, and, if the Phase 3 study cannot be completed to its prespecified endpoints, the study would not be able to be used as the pivotal study supporting a marketing application in the United States, and at least one entirely new Phase 3 pivotal study would need to be conducted to provide the pivotal study supporting a marketing application in the United States. Even if the partial clinical hold is lifted, if it is not lifted in a timely fashion, the nature and duration of the partial clinical hold could irreparably harm the data from the Phase 3 study such that it may no longer be able to be used as the pivotal study supporting a marketing application in the United States. Even if the partial clinical hold is lifted in a timely fashion, it remains possible that the regulatory authorities could determine that the Phase 3 study is not sufficient to be used as a single pivotal study supporting a marketing application in the United States.

Stock options, stock bonuses and compensation granted by the Company as of December 31, 2016 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Incentive Stock Options Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">3,460,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,648,966</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,511,334</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">9,680,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,563,284</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,389,098</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">5,594,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,003,926</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,589,247</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">3,350,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,087,257</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,229,692</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">16,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td></tr> </table>   Stock options, stock bonuses and compensation granted by the Company as of September 30, 2016 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%">Incentive Stock Option Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">3,460,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,648,966</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,511,334</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">9,680,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,940,321</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,059,261</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">5,594,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,161,211</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,431,962</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">3,350,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,985,037</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,331,912</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">16,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td></tr> </table>   Stock option activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended December 31,</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Granted</td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%"> </td> <td style="width: 10%; text-align: right">-</td> </tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">377,037</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> </tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">22,966</td> </tr> </table>   Stock-Based Compensation Expense   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three months Ended December 31,</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Employees</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">312,375</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">427,910</td> </tr> <tr style="vertical-align: bottom"> <td>Non-employees</td> <td> </td> <td>$</td> <td style="text-align: right">78,553</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">329,195</td> </tr> </table>     Employee compensation expense includes the expense related to options issued or vested and restricted stock. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts.   Warrants and Non-employee Options   The following chart presents the outstanding warrants and non-employee options, listed by expiration date at December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Warrant</td> <td style="text-align: center">Issue Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issuable upon Exercise of Warrant</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center">Expiration Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Reference</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series P</td> <td style="text-align: right">2/10/12</td> <td> </td> <td> </td> <td style="text-align: right">590,001</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.50</td> <td> </td> <td style="text-align: right">3/6/17</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 33%">Series DD</td> <td style="width: 14%; text-align: right">12/8/16</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">34,024,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.18</td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">6/8/17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE</td> <td style="text-align: right">12/8/16</td> <td> </td> <td> </td> <td style="text-align: right">34,024,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.18</td> <td> </td> <td style="text-align: right">9/8/17</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series N</td> <td style="text-align: right">8/18/08</td> <td> </td> <td> </td> <td style="text-align: right">2,844,627</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.53</td> <td> </td> <td style="text-align: right">8/18/17</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series U</td> <td style="text-align: right">4/17/14</td> <td> </td> <td> </td> <td style="text-align: right">445,514</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.75</td> <td> </td> <td style="text-align: right">10/17/17</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series S</td> <td style="text-align: right">10/11/13 -10/24/14</td> <td> </td> <td> </td> <td style="text-align: right">25,928,010</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.25</td> <td> </td> <td style="text-align: right">10/11/18</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V</td> <td style="text-align: right">5/28/15</td> <td> </td> <td> </td> <td style="text-align: right">20,253,164</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.79</td> <td> </td> <td style="text-align: right">5/28/20</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W</td> <td style="text-align: right">10/28/15</td> <td> </td> <td> </td> <td style="text-align: right">17,223,248</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.67</td> <td> </td> <td style="text-align: right">10/28/20</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series X</td> <td style="text-align: right">1/13/16</td> <td> </td> <td> </td> <td style="text-align: right">3,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.37</td> <td> </td> <td style="text-align: right">1/13/21</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Y</td> <td style="text-align: right">2/15/16</td> <td> </td> <td> </td> <td style="text-align: right">650,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.48</td> <td> </td> <td style="text-align: right">2/15/21</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z</td> <td style="text-align: right">5/23/16</td> <td> </td> <td> </td> <td style="text-align: right">6,600,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">11/23/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ</td> <td style="text-align: right">5/23/16</td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">5/18/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB</td> <td style="text-align: right">8/26/16</td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">8/22/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF</td> <td style="text-align: right">12/8/16</td> <td> </td> <td> </td> <td style="text-align: right">1,701,200</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.16</td> <td> </td> <td style="text-align: right">12/1/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC</td> <td style="text-align: right">12/8/16</td> <td> </td> <td> </td> <td style="text-align: right">17,012,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.20</td> <td> </td> <td style="text-align: right">12/8/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA</td> <td style="text-align: right">8/26/16</td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">2/22/22</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Consultants</td> <td style="text-align: right">3/6/12- 7/1/16</td> <td> </td> <td> </td> <td style="text-align: right">575,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.37- $3.50</td> <td> </td> <td style="text-align: right">3/5/17- 6/30/19</td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> </table>   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt">1.</td> <td style="padding: 0.75pt; text-decoration: underline; text-align: justify">Derivative Liabilities</td></tr> </table>   The table below presents the warrant liabilities and their respective balances at the balance sheet dates:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">490,040</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,111,361</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">202,532</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,620,253</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">132,254</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,799,858</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">101,817</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">970,604</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">6,725</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,609</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">84,092</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">763,661</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">5,916</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">58,588</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">455,931</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">72,353</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">176,804</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">54,242</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,782,706</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,394,934</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The table below presents the gains on the warrant liabilities for the three months ended December 31:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,621,321</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,826,153</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31,186</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,417,721</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,240,506</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,667,604</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,025,115</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">868,787</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">63,884</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">679,569</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">52,672</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">604,492</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">370,919</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">514,603</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">66,740</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net gain on warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,928,312</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,122,960</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.   In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.   Issuance of additional Warrants   On December 8, 2016, the Company sold 34,024,000 shares of common stock and warrants to purchase common stock at a price of $0.125 in a public offering. The warrants consist of 17,012,000 Series CC warrants to purchase 17,012,000 shares of common stock, 34,024,000 Series DD warrants to purchase 34,024,000 shares of common stock and 34,024,000 Series EE warrants to purchase 34,024,000 shares of common stock. The Series CC warrants are immediately exercisable, expire in five-years from the offering date and have an exercise price of $0.20 per share. The Series DD warrants are immediately exercisable, expire in six-months from the offering date and have an exercise price of $0.18 per share. The Series EE warrants are immediately exercisable, expire in nine-months from the offering date and have an exercise price of $0.18 per share. In addition, the Company issued 1,701,200 Series FF warrants to purchase 1,701,200 shares of common stock to the placement agent. The FF warrants are exercisable at any time on or after June 8, 2017 and expire on December 1, 2021 and have an exercise price $0.15625. The net proceeds from this offering was approximately $3.7 million. The fair value of the Series CC, DD, EE and FF warrants of approximately $2.3 million on the date of issuance was recorded as a warrant liability.   Expiration of Warrants   On December 6, 2016, 2,625,000 Series R warrants, with an exercise price of $4.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.   On December 22, 2015, 1,200,000 Series Q warrants, with an exercise price of $5.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 48px; padding: 0.75pt">2.</td> <td style="padding: 0.75pt; text-decoration: underline; text-align: justify">Options and shares issued to Consultants</td></tr> </table>   The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the three months ended December 31, 2016, the Company issued 372,492 shares of common stock, of which 270,000 were restricted shares. The common stock was issued with stock prices ranging between $0.09 and $0.29 per share. During the three months ended December 31, 2015, the Company issued 442,492 shares of common stock, of which 340,000 were restricted shares. The common stock was issued with stock prices ranging between $0.41 and $0.72 per share. Additionally, during the three months ended December 31, 2015, the Company issued a consultant 150,000 options to purchase common stock at $0.60 per share and a fair value of $0.30 per share. The aggregate values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to general and administrative expenses over the periods of service.   During the three months ended December 31, 2016 and 2015, the Company recorded total expense of approximately $79,000 and $329,000, respectively, relating to these consulting agreements. At December 31, 2016 and September 30, 2016, approximately $30,000 and $48,000, respectively, are included in prepaid expenses. As of December 31, 2016, the Company had 575,000 options outstanding, which were issued to consultants as payment for services. Of these 575,000 outstanding options, 475,000 were vested, all of which were issued from the Non-Qualified Stock Option plans.

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.   ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">●</td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">●</td> <td colspan="2" style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding: 0.75pt">●</td> <td colspan="2" style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Unobservable inputs that reflect management’s assumptions</td></tr> </table>    For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">490,040</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,292,666</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,782,706</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">3,111,361</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">5,283,573</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,394,934</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>    The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2016 and the year ended September 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">3 Months Ended</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">12 Months Ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">5,283,573</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">6,323,032</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Issuances</td> <td> </td> <td> </td> <td style="text-align: right">2,316,084</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,722,073</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Realized and unrealized gains</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,306,991</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(9,761,532</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Ending balance</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,292,666</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">5,283,573</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>   The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates, are observable in active markets.

Effective August 31, 2016, Maximilian de Clara, the Company’s then President and a director, resigned for health reasons. In payment for past services, the Company agreed to issue Mr. de Clara 650,000 shares of restricted stock; 325,000 shares upon his resignation and 325,000 on August 31, 2017. At December 31, 2016 and September 30, 2016, the fair value accrued for unissued shares was approximately $22,000 and $101,000, respectively.   On January 13, 2016, the de Clara Trust demanded payment on a note payable, of which the balance, including accrued and unpaid interest, was approximately $1.1 million. The de Clara Trust was established by Maximilian de Clara, the Company’s former President and a director. The Company’s Chief Executive Officer, Geert Kersten, is the trustee and a beneficiary. When the de Clara Trust demanded payment on the note, the Company sold 3,000,000 shares of its common stock and 3,000,000 Series X warrants to the de Clara Trust for approximately $1.1 million. Each warrant allows the de Clara Trust to purchase one share of the Company's common stock at a price of $0.37 per share at any time on or before January 13, 2021.   During the three months ended December 31, 2016 and 2015, the Company paid approximately $0 and $33,000, respectively, in interest expense to Mr. de Clara.

Clinical Research Agreements   In March 2013, the Company entered into an agreement with Aptiv Solutions, Inc. (which was subsequently acquired by ICON Inc.) to provide certain clinical research services in accordance with a master service agreement. The Company will reimburse ICON for costs incurred. The agreement required the Company to make $600,000 in advance payments which are being credited against future invoices in $150,000 annual increments through December 2017. As of December 31, 2016, the total balance advanced is $150,000, which is classified as a current asset.   In April 2013, the Company entered into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million towards the study in the form of offering discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into a second co-development and revenue sharing agreement with Ergomed for an additional $2 million, for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed, it has incurred research and development expenses of approximately $20.4 million related to Ergomed’s services. This amount is net of Ergomed’s discount of approximately $6.6 million. During the three months ended December 31, 2016 and 2015, the Company recorded, net of Ergomed’s discount, approximately $1.3 million and $2.0 million, respectively, as research and development expense related to Ergomed’s services.   In October 2013, the Company entered into two co-development and profit sharing agreements with Ergomed.  One agreement supports the Phase 1 study being conducted at the University of California, San Francisco, or UCSF, for the development of Multikine as a potential treatment for peri-anal warts in HIV/HPV co-infected men and women.  The Phase 1 study originally started after the Company signed a cooperative research and development agreement with the U.S. Naval Medical Center, San Diego. In August 2016, the U.S. Navy discontinued this Phase 1 study because of difficulties in enrolling patients. The other agreement focuses on the development of Multikine as a potential treatment for cervical dysplasia in HIV/HPV co-infected women. Ergomed will assume up to $3 million in clinical and regulatory costs for each study.   The Company is currently involved in a pending arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet AG). The Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former third-party CRO, and are seeking payment for damages related to inVentiv’s prior involvement in the Phase 3 clinical trial of Multikine. The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract, (ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in its amended statement of claim.   In an amended statement of claim, the Company asserted the claims set forth above as well as an additional claim for professional malpractice.  The arbitrator subsequently granted inVentiv’s motion to dismiss the professional malpractice claim based on the “economic loss doctrine” which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim alongside a claim for breach of contract.  The arbitrator denied the remainder of inVentiv’s motion, which had sought to dismiss certain other aspects of the amended statement of claim.  In particular, the arbitrator rejected inVentiv’s argument that several aspects of the amended statement of claim were beyond the arbitrator’s jurisdiction.    In connection with the pending arbitration proceedings, inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in damages for services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the alleged use of inVentiv’s name in connection with publications and promotions in violation of the parties’ contract; (iii) opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv’s counterclaims are meritless and intends to vigorously defend against them. However, if such defense is unsuccessful, and inVentiv successfully asserts any of its counterclaims, such an adverse determination could have a material adverse effect on the Company’s business, results, financial condition and liquidity.   In October 2015 the Company signed an arbitration funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding litigation expenses. Pursuant to the agreement, an affiliate of Lake Whillans provides the Company with up to $5 million in funding for litigation expenses to support its arbitration claims against inVentiv. The funding is available to the Company to fund the expenses of the ongoing arbitration and will only be repaid if the Company receives proceeds from the arbitration. During the three months ended December 31, 2015, the Company recognized a gain of approximately $1.1 million on the derecognition of legal fees to record the transfer of the liability that existed prior to the execution of the financing agreement from the Company to Lake Whillans. The gain on derecognition of legal fees is recorded as a reduction of general and administration expenses on the Statement of Operations. All related legal fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to cap its fees and expenses for the arbitration at $5 million.   The arbitration hearing on the merits began on September 26, 2016.   Lease Agreements   The Company leases a building near Baltimore, Maryland. The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease.   The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets at December 31, 2016 and September 30, 2016.   The Company subleases a portion of its rental space on a month-to-month term lease, which requires a 30 day notice for termination. The Company receives approximately $6,000 per month in rent for the sub-leased space.   The Company leases its research and development laboratory under a 60 month lease which expires February 28, 2017. In September 2016, the lease was extended through February 28, 2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate of approximately $11,000 per month. As of December 31, 2016 and September 30, 2016, the Company has recorded a deferred rent liability of approximately $1,000 and $2,000, respectively.   The Company leases its office headquarters under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per month. As of December 31, 2016 and September 30, 2016, the Company has recorded a deferred rent liability of approximately $18,000.   During the three months ended December 31, 2016, the Company leased office equipment under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment is $505. The lease bears interest at approximately 6.25% per annum. The Company’s previous equipment lease expired on September 30, 2016.

During the three months ended December 31, 2016 and 2015, no patent impairment charges were recorded. For the three months ended December 31, 2016 and 2015, amortization of patent costs totaled approximately $9,000. The total estimated future amortization expense is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 87%">Nine months ending September 30, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">27,433</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2018</td> <td> </td> <td> </td> <td style="text-align: right">36,379</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2019</td> <td> </td> <td> </td> <td style="text-align: right">34,676</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2020</td> <td> </td> <td> </td> <td style="text-align: right">31,483</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">28,183</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">24,380</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">64,733</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">247,267</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

The following table provides the details of the basic and diluted earnings per-share computations: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended December 31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Income</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">EPS</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> </tr> <tr style="vertical-align: bottom"> <td style="width: 58%; text-align: justify">Basic earnings per share</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">3,536,802</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double"> </td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">149,860,777</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">0.02</td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivatives (1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,556,754</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,256,934</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive earnings per share</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,980,048</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">152,117,711</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">0.01</td> </tr> </table>   (1) Includes certain Series CC, DD, EE and FF warrants.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Income</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">EPS</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> </tr> <tr style="vertical-align: bottom"> <td style="width: 58%; text-align: justify">Basic earnings per share</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">2,341,813</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double"> </td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">109,768,502</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">0.02</td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Conversion of note payable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">24,841</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,871,283</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive earnings per share</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">2,366,654</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">111,639,785</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">0.02</td> </tr> </table>   The gain on derivatives priced lower than the average market price during the period is excluded from the numerator and the related shares are excluded from the denominator in calculating diluted loss per share.   In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Options and Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">173,654,474</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">74,776,529</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Unvested Restricted Stock</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,100,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15,100,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">188,754,474</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">89,876,529</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2016.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2016 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2016 is derived from the September 30, 2016 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2016 and 2015 are not necessarily indicative of the results to be expected for the entire year.   The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and development costs are expensed as incurred.

The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of December 31, 2016 and September 30, 2016.

The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.   The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.   The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.   Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.

Stock-Based Compensation Expense   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three months Ended December 31,</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="width: 72%">Employees</td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">312,375</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 0%">$</td> <td style="width: 10%; text-align: right">427,910</td> </tr> <tr style="vertical-align: bottom"> <td>Non-employees</td> <td> </td> <td>$</td> <td style="text-align: right">78,553</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">329,195</td> </tr> </table>

The following chart presents the outstanding warrants and non-employee options, listed by expiration date at December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>Warrant</td> <td style="text-align: center">Issue Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issuable upon Exercise of Warrant</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center">Expiration Date</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Reference</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series P</td> <td style="text-align: right">2/10/12</td> <td> </td> <td> </td> <td style="text-align: right">590,001</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">4.50</td> <td> </td> <td style="text-align: right">3/6/17</td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 33%">Series DD</td> <td style="width: 14%; text-align: right">12/8/16</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">34,024,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.18</td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">6/8/17</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE</td> <td style="text-align: right">12/8/16</td> <td> </td> <td> </td> <td style="text-align: right">34,024,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.18</td> <td> </td> <td style="text-align: right">9/8/17</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series N</td> <td style="text-align: right">8/18/08</td> <td> </td> <td> </td> <td style="text-align: right">2,844,627</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.53</td> <td> </td> <td style="text-align: right">8/18/17</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series U</td> <td style="text-align: right">4/17/14</td> <td> </td> <td> </td> <td style="text-align: right">445,514</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.75</td> <td> </td> <td style="text-align: right">10/17/17</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series S</td> <td style="text-align: right">10/11/13 -10/24/14</td> <td> </td> <td> </td> <td style="text-align: right">25,928,010</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.25</td> <td> </td> <td style="text-align: right">10/11/18</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V</td> <td style="text-align: right">5/28/15</td> <td> </td> <td> </td> <td style="text-align: right">20,253,164</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.79</td> <td> </td> <td style="text-align: right">5/28/20</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W</td> <td style="text-align: right">10/28/15</td> <td> </td> <td> </td> <td style="text-align: right">17,223,248</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.67</td> <td> </td> <td style="text-align: right">10/28/20</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series X</td> <td style="text-align: right">1/13/16</td> <td> </td> <td> </td> <td style="text-align: right">3,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.37</td> <td> </td> <td style="text-align: right">1/13/21</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Y</td> <td style="text-align: right">2/15/16</td> <td> </td> <td> </td> <td style="text-align: right">650,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.48</td> <td> </td> <td style="text-align: right">2/15/21</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z</td> <td style="text-align: right">5/23/16</td> <td> </td> <td> </td> <td style="text-align: right">6,600,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">11/23/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ</td> <td style="text-align: right">5/23/16</td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">5/18/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB</td> <td style="text-align: right">8/26/16</td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">8/22/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF</td> <td style="text-align: right">12/8/16</td> <td> </td> <td> </td> <td style="text-align: right">1,701,200</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.16</td> <td> </td> <td style="text-align: right">12/1/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC</td> <td style="text-align: right">12/8/16</td> <td> </td> <td> </td> <td style="text-align: right">17,012,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.20</td> <td> </td> <td style="text-align: right">12/8/21</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA</td> <td style="text-align: right">8/26/16</td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.55</td> <td> </td> <td style="text-align: right">2/22/22</td> <td> </td> <td> </td> <td style="text-align: right">1</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Consultants</td> <td style="text-align: right">3/6/12- 7/1/16</td> <td> </td> <td> </td> <td style="text-align: right">575,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.37- $3.50</td> <td> </td> <td style="text-align: right">3/5/17- 6/30/19</td> <td> </td> <td> </td> <td style="text-align: right">2</td> <td> </td></tr> </table>   The table below presents the warrant liabilities and their respective balances at the balance sheet dates:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">490,040</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,111,361</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">202,532</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,620,253</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">132,254</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,799,858</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">101,817</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">970,604</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">6,725</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">70,609</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">84,092</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">763,661</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">5,916</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">58,588</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">455,931</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">72,353</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">176,804</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">54,242</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Total warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,782,706</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,394,934</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The table below presents the gains on the warrant liabilities for the three months ended December 31:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2015</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,621,321</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">2,826,153</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series U warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">31,186</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,417,721</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,240,506</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,667,604</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,025,115</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">868,787</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">63,884</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">679,569</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">52,672</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">604,492</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">370,919</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">514,603</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">66,740</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net gain on warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,928,312</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,122,960</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">490,040</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,292,666</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,782,706</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Derivative instruments</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">3,111,361</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">5,283,573</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">8,394,934</td> <td style="padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended December 31, 2016 and the year ended September 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">3 Months Ended</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center">12 Months Ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">December 31, 2016</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">September 30, 2016</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%">Beginning balance</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">5,283,573</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">6,323,032</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Issuances</td> <td> </td> <td> </td> <td style="text-align: right">2,316,084</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">8,722,073</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Realized and unrealized gains</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,306,991</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(9,761,532</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Ending balance</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,292,666</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">5,283,573</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>

The total estimated future amortization expense is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 87%">Nine months ending September 30, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">27,433</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2018</td> <td> </td> <td> </td> <td style="text-align: right">36,379</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2019</td> <td> </td> <td> </td> <td style="text-align: right">34,676</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2020</td> <td> </td> <td> </td> <td style="text-align: right">31,483</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">28,183</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">24,380</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">64,733</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">247,267</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

The following table provides the details of the basic and diluted earnings per-share computations:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended December 31, 2016</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Income</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">EPS</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> </tr> <tr style="vertical-align: bottom"> <td style="width: 58%; text-align: justify">Basic earnings per share</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">3,536,802</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double"> </td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">149,860,777</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">0.02</td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Gain on derivatives (1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,556,754</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,256,934</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive earnings per share</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">1,980,048</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">152,117,711</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">0.01</td> </tr> </table>   (1) Includes certain Series CC, DD, EE and FF warrants.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Net Income</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">EPS</td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> </tr> <tr style="vertical-align: bottom"> <td style="width: 58%; text-align: justify">Basic earnings per share</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">2,341,813</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double"> </td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">109,768,502</td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 1%; padding-bottom: 3pt"> </td> <td style="width: 0%; border-bottom: black 1.5pt double">$</td> <td style="width: 10%; border-bottom: black 1.5pt double; text-align: right">0.02</td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Conversion of note payable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">24,841</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,871,283</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> </tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dilutive earnings per share</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">2,366,654</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">111,639,785</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1.5pt double">$</td> <td style="border-bottom: black 1.5pt double; text-align: right">0.02</td> </tr> </table>

173654474 74776529 15100000 15100000

89879529

188754474

2341813

3536802

-1556754

2366654

1980048

2256934

24841

1871283

9000

27433

36379

34676

31483

28183

24380

64733

33000

1292666

5283573

6323032

2316084

8722073

-6306991

-9761532

490040

3111361

1292666

5283573

1782706

8394934

1511334

2389098

1589247

1229692

400000

1511334

2059261

2431962

1331912

400000

4003926

2087257

15600000

3161211

1985037

15600000

1648966

6563284

1648966

6940321

3460000

9680000

5594000

3350000

16000000

3460000

9680000

5594000

3350000

16000000

377037

22966

427910

312375

329195 78553 1782706 8394934 54242 0 176804 0 72353 0 455931 0 5916 58588 84092 763661 6725 70609 101817 970604 132254 1799858 202532 1620253 0 0 490040 3111361

8122960

8928312

0 66740 0 514603 0 370919 0 604492 0 52672 0 679569 0 63884 0 868787 2025115 1667604 3240506 1417721 31186 0 2826153 2621321 8/18/2008 2/10/2012 3/6/12- 7/1/16 10/11/13 -10/24/14 4/17/2014 5/28/2015 10/28/2015 2/15/2016 1/13/2016 12/8/2016 12/8/2016 5/23/2016 5/23/2016 8/26/2016 12/8/2016 12/8/2016 8/26/2016 17223248 20253164 590001 575000 25928010 445514 3000000 650000 2844627 34024000 34024000 6600000 500000 400000 1701200 17012000 5000000 0.67 0.79 4.5 1.25 1.75 0.37 0.48 0.53 0.18 0.18 0.55 0.55 0.55 0.16 0.2 0.55 .37 3.50 8/18/2017 3/6/2017 3/5/17- 6/30/19 10/11/2018 10/17/2017 5/28/2020 10/28/2020 2/15/2021 1/13/2021 6/8/2017 9/8/2017 11/23/2021 5/18/2021 8/22/2021 12/1/2021 12/8/2021 2/22/2022

20976

17258

6814

26104

5060771 2316084 Includes certain Series CC, DD, EE and FF warrants.

EX-101.SCH 5 cvm-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - B. OPERATIONS AND FINANCING link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - C. STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - F. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - G. PATENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - H. EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - I. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - G. PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - H. LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - C. STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - E. RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - G. PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - G. PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - H. LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - H. LOSS PER COMMON SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cvm-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 cvm-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 cvm-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Series W [Member] Class Of Warrant Or Right [Axis] Series V [Member] Series P [Member] Consultants [Member] Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) FairValueByFairValueHierarchyLevel [Axis] Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Incentive Stock Option Plans Award Type [Axis] Non-Qualified Stock Option Plans Bonus Plans Stock Compensation Plan Series N [Member] Series S [Member] Series U [Member] Incentive Stock Bonus Plan Series X [Member] Series Y [Member] Series DD [Member] Series EE [Member] Series Z [Member] Series ZZ [Member] Series BB [Member] Series FF [Member] Series CC [Member] Series AA [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Receivables Prepaid expenses Deposits - current portion Inventory used for R&D and manufacturing Deferred rent - current portion Total current assets RESEARCH AND OFFICE EQUIPMENT, net PATENT COSTS, net DEFERRED RENT - net of current portion DEPOSITS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) CURRENT LIABILITIES: Accounts payable Accrued expenses Due to employees Derivative instruments, current portion Other current liabilities Total current liabilities Derivative instruments - net of current portion Deferred revenue Other Liabilities Total liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY (DEFICIT) Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding Common stock, $.01 par value - 600,000,000 shares authorized, 190,931,286 and 155,962,079 shares issued and outstanding at December 31, 2016 and September 30, 2016, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity (deficit) TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Assets Accumulated Depreciation and Amortization for Research and Office Equipment and Leasehold Improvements Accumulated Amortization for Patents Stockholders Equity Preferred Stock Shares Par Value Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Outstanding Common Stock Shares Par Value Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Outstanding Income Statement [Abstract] GRANT INCOME AND OTHER OPERATING EXPENSES: Research and development Depreciation and amortization General & administrative Total operating expenses OPERATING LOSS GAIN ON DERIVATIVE INSTRUMENTS LOSS ON DEBT EXTINGUISHMENT INTEREST INCOME, NET INTEREST EXPENSE NET INCOME AVAILABLE TO COMMON SHAREHOLDERS NET INCOME PER COMMON SHARE BASIC DILUTED BASIC and DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING BASIC DILUTED BASIC AND DILUTED Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net income Adjustments to reconcile net income to net cash used in operating activities: Depreciation and amortization Issuance of common stock and options for services Modification of warrants issued to consultants Equity based compensation Common stock contributed to 401(k) plan Impairment loss on abandonment of patents Loss on retired equipment Gain on derivative instruments Loss on debt extinguishment (Increase)/decrease in assets: Receivables Deferred rent Prepaid expenses Inventory used for R&D and manufacturing Deposits Increase/(decrease) in liabilities: Accounts payable Accrued expenses Deferred revenue Due to employees Deferred rent liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of equipment Expenditures for patent costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants Proceeds from exercise of warrants Payments on related party loan Payments on obligations under capital lease Net cash provided by financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Decrease in receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services Research and office equipment included in accounts payable at year end Capital lease payments included in accounts payable Property and equipment acquired through capital lease Fair value of warrants issued in connection with public offering Financing costs included in accounts payable Prepaid consulting services paid with issuance of common stock Cash paid for interest expense Notes to Financial Statements A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES B. OPERATIONS AND FINANCING C. STOCKHOLDERS' EQUITY Fair Value Disclosures [Abstract] D. FAIR VALUE MEASUREMENTS E. RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] F. COMMITMENTS AND CONTINGENCIES Accounting Policies [Abstract] G. PATENTS H. EARNINGS PER COMMON SHARE Subsequent Events [Abstract] I. SUBSEQUENT EVENTS A. Summary Of Significant Accounting Policies Policies Basis of Presentation Research and Office Equipment and Leasehold Improvements Patents Research and Development Costs Income Taxes Derivative Instruments Deferred Rent (Asset) Stock-Based Compensation New Accounting Pronouncements C. Stockholders Equity Tables Stock options, stock bonuses and compensation granted by the Company Schedule of employees and non-employees stock compensation Derivative Liabilities, Warrants and Other Options Tabular disclosure of derivative liabilities at fair value Schedule Of Gains and (Losses) on Derivative Liabilities D. Fair Value Measurements Tables Measured at fair value on a recurring basis Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) G. Patents Tables Schedule of total estimated future amortization EX-101.PRE 9 cvm-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2016	Feb. 03, 2017
Document And Entity Information
Entity Registrant Name	CEL SCI CORP
Entity Central Index Key	0000725363
Document Type	10-Q
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		190,965,450
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2017

XML 11 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Dec. 31, 2016	Sep. 30, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 2,386,673	$ 2,917,996
Receivables	4,128	394,515
Prepaid expenses	866,987	981,677
Deposits - current portion	154,995	154,995
Inventory used for R&D and manufacturing	694,504	1,008,642
Deferred rent - current portion	415,003	429,821
Total current assets	4,522,290	5,887,646
RESEARCH AND OFFICE EQUIPMENT, net	229,676	226,216
PATENT COSTS, net	247,267	256,547
DEFERRED RENT - net of current portion	3,257,739	3,406,921
DEPOSITS	1,670,917	1,820,917
TOTAL ASSETS	9,927,889	11,598,247
CURRENT LIABILITIES:
Accounts payable	2,741,353	3,091,512
Accrued expenses	319,476	378,672
Due to employees	476,413	538,278
Derivative instruments, current portion	249,157	0
Other current liabilities	7,203	3,310
Total current liabilities	3,793,602	4,011,772
Derivative instruments - net of current portion	1,533,549	8,394,934
Deferred revenue	125,000	125,000
Other Liabilities	42,447	22,609
Total liabilities	5,494,598	12,554,315
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding	0	0
Common stock, $.01 par value - 600,000,000 shares authorized, 190,931,286 and 155,962,079 shares issued and outstanding at December 31, 2016 and September 30, 2016, respectively	1,909,313	1,559,621
Additional paid-in capital	284,655,153	283,152,288
Accumulated deficit	(282,131,175)	(285,667,977)
Total stockholders' equity (deficit)	4,433,291	(956,068)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 9,927,889	$ 11,598,247

XML 12 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Sep. 30, 2016
Stockholders Equity
Preferred Stock Shares Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	200,000	200,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Shares Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	600,000,000	600,000,000
Common Stock Shares Issued	190,931,286	155,962,079
Common Stock Shares Outstanding	190,931,286	155,962,079

XML 13 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
GRANT INCOME AND OTHER	$ 17,258	$ 20,976
OPERATING EXPENSES:
Research and development	4,024,856	5,169,507
General & administrative	1,407,009	634,601
Total operating expenses	5,431,865	5,804,108
OPERATING LOSS	(5,414,607)	(5,783,132)
GAIN ON DERIVATIVE INSTRUMENTS	8,928,312	8,122,960
INTEREST INCOME, NET	23,097	1,985
NET INCOME AVAILABLE TO COMMON SHAREHOLDERS	$ 3,536,802	$ 2,341,813
NET INCOME PER COMMON SHARE
BASIC	$ 0.02	$ 0.02
DILUTED	$ 0.01	$ 0.02
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC	149,860,777	109,768,502
DILUTED	152,117,711	111,639,785

XML 14 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 3,536,802	$ 2,341,813
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	30,737	41,741
Issuance of common stock and options for services	78,553	329,195
Equity based compensation	312,375	427,910
Common stock contributed to 401(k) plan	38,372	40,995
Loss on retired equipment	1,187	115
Gain on derivative instruments	(8,928,312)	(8,122,960)
(Increase)/decrease in assets:
Receivables	85,046	75,206
Deferred rent	164,000	176,825
Prepaid expenses	96,507	51,628
Inventory used for R&D and manufacturing	314,138	58,798
Deposits	150,000	150,000
Increase/(decrease) in liabilities:
Accounts payable	(75,029)	(1,666,792)
Accrued expenses	(59,196)	280,032
Deferred revenue	0	(1,639)
Due to employees	17,110	(25,056)
Deferred rent liability	(1,496)	4,245
Net cash used in operating activities	(4,239,206)	(5,837,944)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	0	(14,831)
Net cash used in investing activities	0	(14,831)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	3,709,931	10,550,538
Payments on obligations under capital lease	(2,048)	(2,194)
Net cash provided by financing activities	3,707,883	10,548,344
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(531,323)	4,695,569
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	2,917,996	5,726,682
CASH AND CASH EQUIVALENTS, END OF PERIOD	2,386,673	10,422,251
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Decrease in receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services	305,341	366,267
Research and office equipment included in accounts payable at year end	0	6,814
Capital lease payments included in accounts payable	372	739
Property and equipment acquired through capital lease	26,104	0
Fair value of warrants issued in connection with public offering	2,316,084	5,060,771
Financing costs included in accounts payable	77,987	21,000
Prepaid consulting services paid with issuance of common stock	(18,183)	8,177
Cash paid for interest expense	$ 12	$ 33,260

XML 15 R6.htm IDEA: XBRL DOCUMENT

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2016

Notes to Financial Statements

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements - Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2016 and September 30, 2016.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.

Deferred Rent (Asset) –Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period.

New Accounting Pronouncements

XML 16 R7.htm IDEA: XBRL DOCUMENT

B. OPERATIONS AND FINANCING

3 Months Ended

Dec. 31, 2016

Notes to Financial Statements

B. OPERATIONS AND FINANCING

As of December 31, 2016, the Phase 3 clinical trial for Multikine was on a partial clinical hold.

XML 17 R8.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY

3 Months Ended

Dec. 31, 2016

Notes to Financial Statements

C. STOCKHOLDERS' EQUITY

Stock options, stock bonuses and compensation granted by the Company as of December 31, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		3,460,000		1,648,966		N/A		1,511,334
Non-Qualified Stock Option Plans		9,680,000		6,563,284		N/A		2,389,098
Stock Bonus Plans		5,594,000		N/A		4,003,926		1,589,247
Stock Compensation Plan		3,350,000		N/A		2,087,257		1,229,692
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		3,460,000		1,648,966		N/A		1,511,334
Non-Qualified Stock Option Plans		9,680,000		6,940,321		N/A		2,059,261
Bonus Plans		5,594,000		N/A		3,161,211		2,431,962
Stock Compensation Plan		3,350,000		N/A		1,985,037		1,331,912
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock option activity:

	Three Months Ended December 31,
	2016		2015
Granted		-		-
Expired		377,037		-
Forfeited		-		22,966

Stock-Based Compensation Expense

	Three months Ended December 31,
	2016		2015
Employees	$	312,375	$	427,910
Non-employees	$	78,553	$	329,195

Warrants and Non-employee Options

The following chart presents the outstanding warrants and non-employee options, listed by expiration date at December 31, 2016:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant		Exercise Price		Expiration Date	Reference

Series P	2/10/12		590,001	$	4.50	3/6/17
Series DD	12/8/16		34,024,000	$	0.18	6/8/17		1
Series EE	12/8/16		34,024,000	$	0.18	9/8/17		1
Series N	8/18/08		2,844,627	$	0.53	8/18/17
Series U	4/17/14		445,514	$	1.75	10/17/17		1
Series S	10/11/13 -10/24/14		25,928,010		1.25	10/11/18		1
Series V	5/28/15		20,253,164	$	0.79	5/28/20		1
Series W	10/28/15		17,223,248	$	0.67	10/28/20		1
Series X	1/13/16		3,000,000	$	0.37	1/13/21
Series Y	2/15/16		650,000	$	0.48	2/15/21
Series Z	5/23/16		6,600,000	$	0.55	11/23/21		1
Series ZZ	5/23/16		500,000	$	0.55	5/18/21		1
Series BB	8/26/16		400,000	$	0.55	8/22/21		1
Series FF	12/8/16		1,701,200	$	0.16	12/1/21		1
Series CC	12/8/16		17,012,000	$	0.20	12/8/21		1
Series AA	8/26/16		5,000,000	$	0.55	2/22/22		1
Consultants	3/6/12- 7/1/16		575,000	$	0.37- $3.50	3/5/17- 6/30/19		2

1.	Derivative Liabilities

The table below presents the warrant liabilities and their respective balances at the balance sheet dates:

	December 31, 2016		September 30, 2016
Series S warrants	$	490,040	$	3,111,361
Series U warrants		-		-
Series V warrants		202,532		1,620,253
Series W warrants		132,254		1,799,858
Series Z warrants		101,817		970,604
Series ZZ warrants		6,725		70,609
Series AA warrants		84,092		763,661
Series BB warrants		5,916		58,588
Series CC warrants		455,931		-
Series DD warrants		72,353		-
Series EE warrants		176,804		-
Series FF warrants		54,242		-

Total warrant liabilities	$	1,782,706	$	8,394,934

The table below presents the gains on the warrant liabilities for the three months ended December 31:

	2016		2015
Series S warrants	$	2,621,321	$	2,826,153
Series U warrants		-		31,186
Series V warrants		1,417,721		3,240,506
Series W warrants		1,667,604		2,025,115
Series Z warrants		868,787		-
Series ZZ warrants		63,884		-
Series AA warrants		679,569		-
Series BB warrants		52,672		-
Series CC warrants		604,492		-
Series DD warrants		370,919		-
Series EE warrants		514,603		-
Series FF warrants		66,740		-

Net gain on warrant liabilities	$	8,928,312	$	8,122,960

Issuance of additional Warrants

Expiration of Warrants

On December 6, 2016, 2,625,000 Series R warrants, with an exercise price of $4.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.

On December 22, 2015, 1,200,000 Series Q warrants, with an exercise price of $5.00, expired. The fair value of the Series Q warrants was $0 on the date of expiration.

2.	Options and shares issued to Consultants

XML 18 R9.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS

3 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

D. FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities
●	Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets
●	Level 3 – Unobservable inputs that reflect management’s assumptions

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	490,040	$	-	$	1,292,666	$	1,782,706

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	3,111,361	$	-	$	5,283,573	$	8,394,934

	3 Months Ended			12 Months Ended
	December 31, 2016			September 30, 2016

Beginning balance	$	5,283,573		$	6,323,032
Issuances		2,316,084			8,722,073
Realized and unrealized gains		(6,306,991	)		(9,761,532	)
Ending balance	$	1,292,666		$	5,283,573

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 19 R10.htm IDEA: XBRL DOCUMENT

E. RELATED PARTY TRANSACTIONS

3 Months Ended

Dec. 31, 2016

Notes to Financial Statements

E. RELATED PARTY TRANSACTIONS

During the three months ended December 31, 2016 and 2015, the Company paid approximately $0 and $33,000, respectively, in interest expense to Mr. de Clara.

XML 20 R11.htm IDEA: XBRL DOCUMENT

F. COMMITMENTS AND CONTINGENCIES

3 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

F. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

The arbitration hearing on the merits began on September 26, 2016.

Lease Agreements

XML 21 R12.htm IDEA: XBRL DOCUMENT

G. PATENTS

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

G. PATENTS

Nine months ending September 30, 2017	$	27,433
Year ending September 30,
2018		36,379
2019		34,676
2020		31,483
2021		28,183
2022		24,380
Thereafter		64,733
Total	$	247,267

XML 22 R13.htm IDEA: XBRL DOCUMENT

H. EARNINGS PER COMMON SHARE

3 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

H. EARNINGS PER COMMON SHARE

The following table provides the details of the basic and diluted earnings per-share computations:

	Three Months Ended December 31, 2016
	Net Income			Weighted Average Shares		EPS

Basic earnings per share	$	3,536,802			149,860,777	$	0.02
Gain on derivatives (1)		(1,556,754	)		2,256,934

Dilutive earnings per share	$	1,980,048			152,117,711	$	0.01

(1) Includes certain Series CC, DD, EE and FF warrants.

	Three Months Ended December 31, 2015
	Net Income		Weighted Average Shares		EPS

Basic earnings per share	$	2,341,813		109,768,502	$	0.02
Conversion of note payable		24,841		1,871,283

Dilutive earnings per share	$	2,366,654		111,639,785	$	0.02

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of December 31:

	2016		2015

Options and Warrants		173,654,474		74,776,529
Unvested Restricted Stock		15,100,000		15,100,000
Total		188,754,474		89,876,529

XML 23 R14.htm IDEA: XBRL DOCUMENT

I. SUBSEQUENT EVENTS	3 Months Ended
I. SUBSEQUENT EVENTS	Dec. 31, 2016
Subsequent Events [Abstract]
I. SUBSEQUENT EVENTS	The Company has evaluated subsequent events through the date these financial statements were filed and determined there are no subsequent events that require disclosure.

XML 24 R15.htm IDEA: XBRL DOCUMENT

A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)	3 Months Ended
	Dec. 31, 2016
A. Summary Of Significant Accounting Policies Policies
Basis of Presentation	The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2016. In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of December 31, 2016 and the results of its operations for the three months then ended. The condensed balance sheet as of September 30, 2016 is derived from the September 30, 2016 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements and the annual financial statements. The results of operations for the three months ended December 31, 2016 and 2015 are not necessarily indicative of the results to be expected for the entire year. The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.
Research and Office Equipment and Leasehold Improvements	Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.
Patents	Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.
Research and Development Costs	Research and development costs are expensed as incurred.
Income Taxes	The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of December 31, 2016 and September 30, 2016.
Derivative Instruments	The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument. The derivative liabilities are remeasured at fair value at the end of each interim period as long as they are outstanding.
Deferred Rent (Asset)	Consideration paid, including deposits, related to operating leases is recorded as a deferred rent asset and amortized as rent expense over the lease term. Interest on the deferred rent is calculated at 3% on the funds deposited on the manufacturing facility and is included in deferred rent. This interest income will be used to offset future rent.
Stock-Based Compensation	Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service or vesting period. Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Historical data was used to estimate option exercise and employee termination within the valuation model. The expected term of options represents the period of time that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.
New Accounting Pronouncements	In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its financial statements and related disclosures.

XML 25 R16.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Tables)

3 Months Ended

Dec. 31, 2016

C. Stockholders Equity Tables

Stock options, stock bonuses and compensation granted by the Company

Stock options, stock bonuses and compensation granted by the Company as of December 31, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		3,460,000		1,648,966		N/A		1,511,334
Non-Qualified Stock Option Plans		9,680,000		6,563,284		N/A		2,389,098
Stock Bonus Plans		5,594,000		N/A		4,003,926		1,589,247
Stock Compensation Plan		3,350,000		N/A		2,087,257		1,229,692
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2016 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		3,460,000		1,648,966		N/A		1,511,334
Non-Qualified Stock Option Plans		9,680,000		6,940,321		N/A		2,059,261
Bonus Plans		5,594,000		N/A		3,161,211		2,431,962
Stock Compensation Plan		3,350,000		N/A		1,985,037		1,331,912
Incentive Stock Bonus Plan		16,000,000		N/A		15,600,000		400,000

Stock option activity:

	Three Months Ended December 31,
	2016		2015
Granted		-		-
Expired		377,037		-
Forfeited		-		22,966

Schedule of employees and non-employees stock compensation

Stock-Based Compensation Expense

	Three months Ended December 31,
	2016		2015
Employees	$	312,375	$	427,910
Non-employees	$	78,553	$	329,195

Derivative Liabilities, Warrants and Other Options

The following chart presents the outstanding warrants and non-employee options, listed by expiration date at December 31, 2016:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrant		Exercise Price		Expiration Date	Reference

Series P	2/10/12		590,001	$	4.50	3/6/17
Series DD	12/8/16		34,024,000	$	0.18	6/8/17		1
Series EE	12/8/16		34,024,000	$	0.18	9/8/17		1
Series N	8/18/08		2,844,627	$	0.53	8/18/17
Series U	4/17/14		445,514	$	1.75	10/17/17		1
Series S	10/11/13 -10/24/14		25,928,010		1.25	10/11/18		1
Series V	5/28/15		20,253,164	$	0.79	5/28/20		1
Series W	10/28/15		17,223,248	$	0.67	10/28/20		1
Series X	1/13/16		3,000,000	$	0.37	1/13/21
Series Y	2/15/16		650,000	$	0.48	2/15/21
Series Z	5/23/16		6,600,000	$	0.55	11/23/21		1
Series ZZ	5/23/16		500,000	$	0.55	5/18/21		1
Series BB	8/26/16		400,000	$	0.55	8/22/21		1
Series FF	12/8/16		1,701,200	$	0.16	12/1/21		1
Series CC	12/8/16		17,012,000	$	0.20	12/8/21		1
Series AA	8/26/16		5,000,000	$	0.55	2/22/22		1
Consultants	3/6/12- 7/1/16		575,000	$	0.37- $3.50	3/5/17- 6/30/19		2

Tabular disclosure of derivative liabilities at fair value

The table below presents the warrant liabilities and their respective balances at the balance sheet dates:

	December 31, 2016		September 30, 2016
Series S warrants	$	490,040	$	3,111,361
Series U warrants		-		-
Series V warrants		202,532		1,620,253
Series W warrants		132,254		1,799,858
Series Z warrants		101,817		970,604
Series ZZ warrants		6,725		70,609
Series AA warrants		84,092		763,661
Series BB warrants		5,916		58,588
Series CC warrants		455,931		-
Series DD warrants		72,353		-
Series EE warrants		176,804		-
Series FF warrants		54,242		-

Total warrant liabilities	$	1,782,706	$	8,394,934

Schedule Of Gains and (Losses) on Derivative Liabilities

The table below presents the gains on the warrant liabilities for the three months ended December 31:

	2016		2015
Series S warrants	$	2,621,321	$	2,826,153
Series U warrants		-		31,186
Series V warrants		1,417,721		3,240,506
Series W warrants		1,667,604		2,025,115
Series Z warrants		868,787		-
Series ZZ warrants		63,884		-
Series AA warrants		679,569		-
Series BB warrants		52,672		-
Series CC warrants		604,492		-
Series DD warrants		370,919		-
Series EE warrants		514,603		-
Series FF warrants		66,740		-

Net gain on warrant liabilities	$	8,928,312	$	8,122,960

XML 26 R17.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Dec. 31, 2016

D. Fair Value Measurements Tables

Measured at fair value on a recurring basis

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	490,040	$	-	$	1,292,666	$	1,782,706

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2016:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total

Derivative instruments	$	3,111,361	$	-	$	5,283,573	$	8,394,934

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

	3 Months Ended			12 Months Ended
	December 31, 2016			September 30, 2016

Beginning balance	$	5,283,573		$	6,323,032
Issuances		2,316,084			8,722,073
Realized and unrealized gains		(6,306,991	)		(9,761,532	)
Ending balance	$	1,292,666		$	5,283,573

XML 27 R18.htm IDEA: XBRL DOCUMENT

G. PATENTS (Tables)

3 Months Ended

Dec. 31, 2016

G. Patents Tables

Schedule of total estimated future amortization

The total estimated future amortization expense is as follows:

Nine months ending September 30, 2017	$	27,433
Year ending September 30,
2018		36,379
2019		34,676
2020		31,483
2021		28,183
2022		24,380
Thereafter		64,733
Total	$	247,267

XML 28 R19.htm IDEA: XBRL DOCUMENT

H. LOSS PER COMMON SHARE (Tables)

3 Months Ended

Dec. 31, 2016

H. Loss Per Common Share Tables

Computation of dilutive net loss per share

The following table provides the details of the basic and diluted earnings per-share computations:

	Three Months Ended December 31, 2016
	Net Income			Weighted Average Shares		EPS

Basic earnings per share	$	3,536,802			149,860,777	$	0.02
Gain on derivatives (1)		(1,556,754	)		2,256,934

Dilutive earnings per share	$	1,980,048			152,117,711	$	0.01

(1) Includes certain Series CC, DD, EE and FF warrants.

	Three Months Ended December 31, 2015
	Net Income		Weighted Average Shares		EPS

Basic earnings per share	$	2,341,813		109,768,502	$	0.02
Conversion of note payable		24,841		1,871,283

Dilutive earnings per share	$	2,366,654		111,639,785	$	0.02

XML 29 R20.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details) - shares	Dec. 31, 2016	Sep. 30, 2016
Incentive Stock Option Plans
Total Shares Reserved Under Plans	3,460,000	3,460,000
Shares Reserved for Outstanding Options	1,648,966	1,648,966
Remaining Options/Shares Under Plans	1,511,334	1,511,334
Non-Qualified Stock Option Plans
Total Shares Reserved Under Plans	9,680,000	9,680,000
Shares Reserved for Outstanding Options	6,563,284	6,940,321
Remaining Options/Shares Under Plans	2,389,098	2,059,261
Bonus Plans
Total Shares Reserved Under Plans	5,594,000	5,594,000
Shares Issued	4,003,926	3,161,211
Remaining Options/Shares Under Plans	1,589,247	2,431,962
Stock Compensation Plan
Total Shares Reserved Under Plans	3,350,000	3,350,000
Shares Issued	2,087,257	1,985,037
Remaining Options/Shares Under Plans	1,229,692	1,331,912
Incentive Stock Bonus Plan
Total Shares Reserved Under Plans	16,000,000	16,000,000
Shares Issued	15,600,000	15,600,000
Remaining Options/Shares Under Plans	400,000	400,000

XML 30 R21.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 1) - shares	3 Months Ended
C. STOCKHOLDERS EQUITY (Details 1) - shares	Dec. 31, 2016	Dec. 31, 2015
C. Stockholders Equity Details 1
Granted	0	0
Expired	377,037	0
Forfeited	0	22,966

XML 31 R22.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 2) - USD ($)	3 Months Ended
C. STOCKHOLDERS EQUITY (Details 2) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
C. Stockholders Equity Details 2
Employees	$ 312,375	$ 427,910
Non-employees	$ 78,553	$ 329,195

XML 32 R23.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 3)	3 Months Ended
C. STOCKHOLDERS EQUITY (Details 3)	Dec. 31, 2016 $ / shares shares
Series P [Member]
STOCKHOLDERS' EQUITY
Issue Date	2/10/2012
Shares Issuable upon Exercise of Warrant \| shares	590,001
Exercise Price	$ 4.5
Expiration Date	3/6/2017
Series DD [Member]
STOCKHOLDERS' EQUITY
Issue Date	12/8/2016
Shares Issuable upon Exercise of Warrant \| shares	34,024,000
Exercise Price	$ 0.18
Expiration Date	6/8/2017
Series EE [Member]
STOCKHOLDERS' EQUITY
Issue Date	12/8/2016
Shares Issuable upon Exercise of Warrant \| shares	34,024,000
Exercise Price	$ 0.18
Expiration Date	9/8/2017
Series N [Member]
STOCKHOLDERS' EQUITY
Issue Date	8/18/2008
Shares Issuable upon Exercise of Warrant \| shares	2,844,627
Exercise Price	$ 0.53
Expiration Date	8/18/2017
Series U [Member]
STOCKHOLDERS' EQUITY
Issue Date	4/17/2014
Shares Issuable upon Exercise of Warrant \| shares	445,514
Exercise Price	$ 1.75
Expiration Date	10/17/2017
Series S [Member]
STOCKHOLDERS' EQUITY
Issue Date	10/11/13 -10/24/14
Shares Issuable upon Exercise of Warrant \| shares	25,928,010
Exercise Price	$ 1.25
Expiration Date	10/11/2018
Series V [Member]
STOCKHOLDERS' EQUITY
Issue Date	5/28/2015
Shares Issuable upon Exercise of Warrant \| shares	20,253,164
Exercise Price	$ 0.79
Expiration Date	5/28/2020
Series W [Member]
STOCKHOLDERS' EQUITY
Issue Date	10/28/2015
Shares Issuable upon Exercise of Warrant \| shares	17,223,248
Exercise Price	$ 0.67
Expiration Date	10/28/2020
Series X [Member]
STOCKHOLDERS' EQUITY
Issue Date	1/13/2016
Shares Issuable upon Exercise of Warrant \| shares	3,000,000
Exercise Price	$ 0.37
Expiration Date	1/13/2021
Series Y [Member]
STOCKHOLDERS' EQUITY
Issue Date	2/15/2016
Shares Issuable upon Exercise of Warrant \| shares	650,000
Exercise Price	$ 0.48
Expiration Date	2/15/2021
Series Z [Member]
STOCKHOLDERS' EQUITY
Issue Date	5/23/2016
Shares Issuable upon Exercise of Warrant \| shares	6,600,000
Exercise Price	$ 0.55
Expiration Date	11/23/2021
Series ZZ [Member]
STOCKHOLDERS' EQUITY
Issue Date	5/23/2016
Shares Issuable upon Exercise of Warrant \| shares	500,000
Exercise Price	$ 0.55
Expiration Date	5/18/2021
Series BB [Member]
STOCKHOLDERS' EQUITY
Issue Date	8/26/2016
Shares Issuable upon Exercise of Warrant \| shares	400,000
Exercise Price	$ 0.55
Expiration Date	8/22/2021
Series FF [Member]
STOCKHOLDERS' EQUITY
Issue Date	12/8/2016
Shares Issuable upon Exercise of Warrant \| shares	1,701,200
Exercise Price	$ 0.16
Expiration Date	12/1/2021
Series CC [Member]
STOCKHOLDERS' EQUITY
Issue Date	12/8/2016
Shares Issuable upon Exercise of Warrant \| shares	17,012,000
Exercise Price	$ 0.2
Expiration Date	12/8/2021
Series AA [Member]
STOCKHOLDERS' EQUITY
Issue Date	8/26/2016
Shares Issuable upon Exercise of Warrant \| shares	5,000,000
Exercise Price	$ 0.55
Expiration Date	2/22/2022
Consultants [Member]
STOCKHOLDERS' EQUITY
Issue Date	3/6/12- 7/1/16
Shares Issuable upon Exercise of Warrant \| shares	575,000
Exercise Price Minimum	$ .37
Exercise Price Maximum	$ 3.50
Expiration Date	3/5/17- 6/30/19

XML 33 R24.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 4) - USD ($)	3 Months Ended
C. STOCKHOLDERS EQUITY (Details 4) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2016
C. Stockholders Equity Details 4
Series S warrants	$ 490,040		$ 3,111,361
Series U warrants	0		0
Series V warrants	202,532		1,620,253
Series W warrants	132,254		1,799,858
Series Z warrants	101,817		970,604
Series ZZ warrants	6,725		70,609
Series AA warrants	84,092		763,661
Series BB warrants	5,916		58,588
Series CC warrants	455,931		0
Series DD warrants	72,353		0
Series EE warrants	176,804		0
Series FF warrants	54,242		0
Total warrant liabilities	1,782,706		$ 8,394,934
Series S warrants	2,621,321	$ 2,826,153
Series U warrants	0	31,186
Series V warrants	1,417,721	3,240,506
Series W warrants	1,667,604	2,025,115
Series Z warrants	868,787	0
Series ZZ warrants	63,884	0
Series AA warrants	679,569	0
Series BB warrants	52,672	0
Series CC warrants	604,492	0
Series DD warrants	370,919	0
Series EE warrants	514,603	0
Series FF warrants	66,740	0
Net gain on warrant liabilities	$ 8,928,312	$ 8,122,960

XML 34 R25.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Derivative instruments	$ 490,040	$ 3,111,361
Significant Other Observable Inputs (Level 2)
Derivative instruments	0	0
Significant Unobservable Inputs (Level 3)
Derivative instruments	1,292,666	5,283,573
Total
Derivative instruments	$ 1,782,706	$ 8,394,934

XML 35 R26.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	3 Months Ended	12 Months Ended
D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
D. Fair Value Measurements Details 1
Beginning balance	$ 5,283,573	$ 6,323,032
Issuances	2,316,084	8,722,073
Realized and unrealized gains	(6,306,991)	(9,761,532)
Ending balance	$ 1,292,666	$ 5,283,573

XML 36 R27.htm IDEA: XBRL DOCUMENT

E. RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
E. Related Party Transactions Details Narrative
Interest expense paid to Mr. de Clara	$ 0	$ 33,000

XML 37 R28.htm IDEA: XBRL DOCUMENT

G. PATENTS (Details) - USD ($)	Dec. 31, 2016	Sep. 30, 2016
G. Patents Details
Nine months ending September 30, 2017	$ 27,433
Year ending September 30, 2018	36,379
Year ending September 30, 2019	34,676
Year ending September 30, 2020	31,483
Year ending September 30, 2021	28,183
Year ending September 30, 2022	24,380
Thereafter	64,733
Total	$ 247,267	$ 256,547

XML 38 R29.htm IDEA: XBRL DOCUMENT

G. PATENTS (Details Narrative) - USD ($)	3 Months Ended
G. PATENTS (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
G. Patents Details Narrative
Patent impairment charges	$ 0	$ 0
Amortization of patent costs	$ 9,000	$ 9,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

H. LOSS PER COMMON SHARE (Details) - USD ($)

3 Months Ended

Dec. 31, 2016

Dec. 31, 2015

H. Loss Per Common Share Details

Net Income

$ 3,536,802

$ 2,341,813

Gain on derivatives

^[1]

(1,556,754)

Conversion of note payable

24,841

Dilutive earnings per share

$ 1,980,048

$ 2,366,654

Weighted Average Shares - Basic

149,860,777

109,768,502

Gain on derivatives, shares

^[1]

2,256,934

Conversion of note payable

1,871,283

Weighted Average Shares - Diluted

152,117,711

111,639,785

Basic earnings per share

$ 0.02

Dilutive earnings per share

$ 0.01

$ 0.02

[1]	Includes certain Series CC, DD, EE and FF warrants.

XML 40 R31.htm IDEA: XBRL DOCUMENT

H. LOSS PER COMMON SHARE (Details 1) - shares	3 Months Ended
H. LOSS PER COMMON SHARE (Details 1) - shares	Dec. 31, 2016	Dec. 31, 2015
H. Loss Per Common Share Details 1
Options and Warrants	173,654,474	74,776,529
Unvested Restricted Stock	15,100,000	15,100,000
Total	188,754,474	89,879,529

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !N"24H?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ &X))2F;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " ;@DE*(*03/>X K @ $0 &1O8U!R;W!S+V-O M&ULS9)12\,P$,>_BN2]O::#B:'KR\0G!<&!XENXW+9@DX;DI-VW-ZU; MA^@'$/*2NW]^]SM(@T%A'^DY]H$B6THWH^M\4A@VXL@<%$#"(SF=RISPN;GO MH]..'/A#45;4&1ZR-9@T3L @+4;2-0861-/?QC#>XX,-G[&:80:". M''E.($L)HITFAM/8-7 %3#"FZ-)W@0 M\/;T^#*O6UB?6'ND_"I9Q:= &W&9_+K:WN\>1%M7\K:HZJ*ZV\FUFD[]/KG^ M\+L*N][8O?W'QA?!MH%?_Z+] E!+ P04 " ;@DE*F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( !N"24KY=1SS>@( .$( 8 >&PO=V]R:W-H965T&UL?5;;CILP$/T5Q <]XZ^BI%1Z;TW=BJU?2MEM@D"<2]H0\<0ZVJJ3 M*^,-D6K);X'H."470VKJ (=A&C2D:OTB-WM'7N3L+NNJI4?NB7O3$/YG3VO6 M;WWDOV\\5[=2ZHV@R#MRHS^H_-D=N5H%DY5+U=!65*SU.+UN_1W:'%"J"0;Q M4M%>S.:>#N7$V*M>?+UL_5![1&MZEMH$4<.#'FA=:TO*C]^C47_2U,3Y_-WZ M9Q.\"N9$!#VP^E=UD>767_O>A5[)O9;/K/]"QX 2WQNC_T8?M%9P[8G2.+-: MF%_O?!>2-:,5Y4I#WH:Q:LW8#RQ+ D, >.W3\K\#!142P0 1&$!EZ-*/',#T&Z;&AQS-Z8EV BTAA@0042!SZ MRA(8$(E!M ,")U&Z< LIJ)(Z*FM+Q45DL, *%%@Y=&1G"@!92)4U*+%V^5:N M[ '(PC5EH$3F\F-+ H DL 0*X9(*70NI750 9K6@LE"XR+5@?W((LZ0"5N\. M8=="9JNX&!PNJ, EC"+7 K)5 Q>4($K';F%C"/KOVC$S&L196&6)G&R%!)< M]<@M>VQGVHA)YYBE5(.K'KE%C9U42YV0<.BD03!K& WE-]-;A7=F]]8T]MGN MU+]WV#2<#_C0_+\3?JM:X9V85&W+-)=# MTQT6DG7C@R*87C7%7U!+ P04 " ;@DE*LX@'0&<$ !#% & 'AL M+W=O' MWS;W_YT+GESK'P.O[]]*_3HU/C7FL^KAN MZW]VFV%[/R_GLTU\KE[KX5M[_#6>&V3GLW/K?X]OL4[RT4FJXZFM^^EW]O3: M#VUS+B59::H?I^MN/UV/Y_+?P^0 / ?@)0#,AP'Z'*!)0'%R-C7U2S54RT77 M'F?=:;0.U3@IX$ZGSGP:7TY]-_V76MNGMV]+](OB;2SG+%F=)'@MN56L!45Y MD12I_HL)%$W@%*^OXX,][,:);AQW0T9@Y5@U8$T(EKCYJ>S&C1?=>.[&$#>>5>/2$"@B6W,9*%4Z M@[*=4K13!&&)-\); M3S*A@2/:4$0#QV\(Z,N2]1,7 MBTWK*#)Z,:+/L.Y@ ",EZ!\]50O@(G)WH# MVE*("$*=.MI"SI,,6>"4-92RP/FI(1B^; 6=+YW/.9(Y"QRTAH(6!(0F8@'K M)*ZSNDRS).-(9BUPV!H*6^ 419.&@ZT0KE.R&90YBYRSAG(6.3\]LL^0H-(: MIR*TGF;+(*6LI95& )Z;T@7ZO?ZZ[=20S%CEC+64L"GDP&CK=UH(L?:Y5 M9I. ,EZ1I\*6IL+(D]PT8B;!G#KBPM1%UNA<=HXRL9$3FX)X)6EH OJQYM:) MS>[.MCS[2'+K0Z8IA$ M3KHMD[4V[;1#;J>H9LHTC3 M_ A!3AL%829M+*Y.<\;CM3^J[F6W[V>/[3"TS71\\]RV0TREJL^IC=M8;2X/ M=7P>QEN?[KO3L=;I86@/YR.[XG)NN/P?4$L#!!0 ( !N"24KVJF)>/P( M + ' 8 >&PO=V]R:W-H965T&ULC97;CILP%$5_!?$! ML;E#1)":5%4KM5(T5:?/3N($- 93VPG3OZ]M& 3&3<)#?-O[G'6(L?..LC=> M8BR<]YHT?..60K1K /BQQ#7B*]KB1JZ<*:N1D$-V ;QE&)VTJ2; AS &-:H: MM\CUW)X5.;T*4C5XSQQ^K6O$_FXQH=W&]=R/B9?J4@HU 8J\11?\$XM?[9[) M$1BCG*H:-[RBC

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end XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 60 183 1 true 26 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cel-sci.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://cel-sci.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://cel-sci.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS Sheet http://cel-sci.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF CASH FLOWS Sheet http://cel-sci.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00000006 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cel-sci.com/role/A.SummaryOfSignificantAccountingPolicies A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 00000007 - Disclosure - B. OPERATIONS AND FINANCING Sheet http://cel-sci.com/role/B.OperationsAndFinancing B. OPERATIONS AND FINANCING Notes 7 false false R8.htm 00000008 - Disclosure - C. STOCKHOLDERS EQUITY Sheet http://cel-sci.com/role/C.StockholdersEquity C. STOCKHOLDERS EQUITY Notes 8 false false R9.htm 00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS Sheet http://cel-sci.com/role/D.FairValueMeasurements D. FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS Sheet http://cel-sci.com/role/E.RelatedPartyTransactions E. RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 00000011 - Disclosure - F. COMMITMENTS AND CONTINGENCIES Sheet http://cel-sci.com/role/F.CommitmentsAndContingencies F. COMMITMENTS AND CONTINGENCIES Notes 11 false false R12.htm 00000012 - Disclosure - G. PATENTS Sheet http://cel-sci.com/role/G.Patents G. PATENTS Notes 12 false false R13.htm 00000013 - Disclosure - H. EARNINGS PER COMMON SHARE Sheet http://cel-sci.com/role/H.EarningsPerCommonShare H. EARNINGS PER COMMON SHARE Notes 13 false false R14.htm 00000014 - Disclosure - I. SUBSEQUENT EVENTS Sheet http://cel-sci.com/role/I.SubsequentEvents I. SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Sheet http://cel-sci.com/role/A.SummaryOfSignificantAccountingPoliciesPolicies A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Notes 15 false false R16.htm 00000016 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) Sheet http://cel-sci.com/role/C.StockholdersEquityTables C. STOCKHOLDERS EQUITY (Tables) Tables http://cel-sci.com/role/C.StockholdersEquity 16 false false R17.htm 00000017 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) Sheet http://cel-sci.com/role/D.FairValueMeasurementsTables D. FAIR VALUE MEASUREMENTS (Tables) Tables http://cel-sci.com/role/D.FairValueMeasurements 17 false false R18.htm 00000018 - Disclosure - G. PATENTS (Tables) Sheet http://cel-sci.com/role/G.PatentsTables G. PATENTS (Tables) Tables http://cel-sci.com/role/G.Patents 18 false false R19.htm 00000019 - Disclosure - H. LOSS PER COMMON SHARE (Tables) Sheet http://cel-sci.com/role/H.LossPerCommonShareTables H. LOSS PER COMMON SHARE (Tables) Tables 19 false false R20.htm 00000020 - Disclosure - C. STOCKHOLDERS EQUITY (Details) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails C. STOCKHOLDERS EQUITY (Details) Details http://cel-sci.com/role/C.StockholdersEquityTables 20 false false R21.htm 00000021 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails1 C. STOCKHOLDERS EQUITY (Details 1) Details http://cel-sci.com/role/C.StockholdersEquityTables 21 false false R22.htm 00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails2 C. STOCKHOLDERS EQUITY (Details 2) Details http://cel-sci.com/role/C.StockholdersEquityTables 22 false false R23.htm 00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails3 C. STOCKHOLDERS EQUITY (Details 3) Details http://cel-sci.com/role/C.StockholdersEquityTables 23 false false R24.htm 00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails4 C. STOCKHOLDERS EQUITY (Details 4) Details http://cel-sci.com/role/C.StockholdersEquityTables 24 false false R25.htm 00000025 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails D. FAIR VALUE MEASUREMENTS (Details) Details http://cel-sci.com/role/D.FairValueMeasurementsTables 25 false false R26.htm 00000026 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails1 D. FAIR VALUE MEASUREMENTS (Details 1) Details http://cel-sci.com/role/D.FairValueMeasurementsTables 26 false false R27.htm 00000027 - Disclosure - E. RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://cel-sci.com/role/E.RelatedPartyTransactionsDetailsNarrative E. RELATED PARTY TRANSACTIONS (Details Narrative) Details http://cel-sci.com/role/E.RelatedPartyTransactions 27 false false R28.htm 00000028 - Disclosure - G. PATENTS (Details) Sheet http://cel-sci.com/role/G.PatentsDetails G. PATENTS (Details) Details http://cel-sci.com/role/G.PatentsTables 28 false false R29.htm 00000029 - Disclosure - G. PATENTS (Details Narrative) Sheet http://cel-sci.com/role/G.PatentsDetailsNarrative G. PATENTS (Details Narrative) Details http://cel-sci.com/role/G.PatentsTables 29 false false R30.htm 00000030 - Disclosure - H. LOSS PER COMMON SHARE (Details) Sheet http://cel-sci.com/role/H.LossPerCommonShareDetails H. LOSS PER COMMON SHARE (Details) Details http://cel-sci.com/role/H.LossPerCommonShareTables 30 false false R31.htm 00000031 - Disclosure - H. LOSS PER COMMON SHARE (Details 1) Sheet http://cel-sci.com/role/H.LossPerCommonShareDetails1 H. LOSS PER COMMON SHARE (Details 1) Details http://cel-sci.com/role/H.LossPerCommonShareTables 31 false false All Reports Book All Reports cvm-20161231.xml cvm-20161231.xsd cvm-20161231_cal.xml cvm-20161231_def.xml cvm-20161231_lab.xml cvm-20161231_pre.xml true true ZIP 47 0001654954-17-000894-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-17-000894-xbrl.zip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�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end